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In the western world, coronary heart disease (CHD) from atherosclerosis kills over 365,000
people annually and is the leading cause of death worldwide. Atherosclerosis can also act
on the blood vessels in the arms or legs causing peripheral arterial disease(PAD), which
affects over 6.5 million people over the age of 40. A standard intervention for CAD/PAD is
a bypass surgery using a vascular graft. Commercially available synthetic grafts are a distant
second option for CAD treatment due to their limited efficacy in smaller diameter vessels.
Synthetic grafts or tissue engineered grafts (TEVG) often fail due to a compliance mismatch
between the native vascular and the graft and an inability to remodel in vivo into a functional
vessel. The ideal bypass graft for treatment of CAD/PAD would be an off-the-shelf graft
that remains patent, compliance-matched, and remodels into a fully functional vessel. The
goal of this dissertation is to use a rat interpositional aortic implantation model to evaluate
the effect of compliance-matching on cellular infiltration in vivo, use transforming growth
factor beta 2 (TGFβ2) to promote a desired in-vivo remodeling response, and develop a new
method to evaluate graft drug delivery and degradation.
The compliance of the TEVGs was tuned to either match or be twice as stiff as rat aorta.
These constructs were subsequently implanted into the abdominal aorta of Sprague Dawley
rats and evaluated in-vivo using ultrasound and at a one-month explantation timepoint.
The compliance-matched TEVGs remained compliant over the time course of the study
and showed desired signs of remodeling with increased ratios of CD163/CD68 macrophages,
increased smooth muscle cells, and increased collagen deposition when compared to the
hypocompliant grafts (p<0.05). TGFβ2 was then added to the TEVG to evaluate cellular
infilatration over an acute 5-day period. The low concentrations of TGFβ2 in the compliance-
matched TEVG were found to increase SMC proliferation while the higher concentrations
decreased the SMC population and promoted collagen deposition (p<0.05). The hypocom-
iv
pliant construct had no differences between all groups and concentrations. Finally, a new
noninvasive method was developed to evaluate TEVG graft design, degradation, and drug
delivery using photoacoustic imaging.
v
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The primary goal of this section is to further describe the basic concepts and methods
covered throughout this dissertation. First, the impact of coronary heart disease (CHD) and
peripheral arterial disease (PAD) will be put into perspective. Next, the basic anatomy of the
blood vessel and the progression of atherosclerosis will be described. The following section
will cover the current treatmentment methods and success rates for CHD/PAD procedures.
Lastly, an in-depth analysis of the tissue engineered vascular graft as an intervention for
CHD/PAD with a discussion of the graft’s fabrication, implantation, and in vivo animal
testing.
1.2 Coronary Heart Disease and Peripheral Arterial Disease Statistics
CHD is caused by the buildup of fatty plaque on the vessel wall (atherosclerosis) that
limits the blood flow to the coronary vasculature, Figure 1-A. This limited blood flow can
result in a heart attack and ultimately lead to death. CHD affects over 18.2 million people
in the United States with over 365,000 deaths annually [1, 2]. This disease is so prevalent
that a heart attack occurs every 40 seconds [1].
PAD is also cause by atheroslcerosis but it acts on the peripheral arteries in the leg or
upper body rather than the coronaries. This disease often goes overlooked as the symptoms
can go unnoticed or be as mild as leg cramping. Severe cases of PAD can manifest into
amputation of the limb or spread throughout the body and to lead to CHD or stroke [3, 4].
In the U.S., PAD is estimated to affect more than 6.5 million people over the age of 40 [5].
As alluded to throughout this section, atherosclerosis is a dangerous and harmful condi-
tion that can affect multiple sections of the body. Finding an improved treatment to combat
this disease is ideal for saving thousands of lives each year.
1
1.3 Surgical Treatment of CHD and PAD
The two main surgical procedures for treating CHD and PAD are bypass surgery or
percutaneous transluminal angioplasty, Figure 1. These procedures help to restore flow to
the disease vessel by either dilating the vessel, compressing the plaque, or diverting flow.
Before going into detail about these procedures, that other methods to treat CHD/PAD
such as atherectomy (removal of plaque), treatment through medication, and diet/exercise,
but these are outside the scope of this dissertation.
The percutaneous route offers a wide array of clinically approved interventions. The first
and oldest intervention is the balloon angioplasty, Figure 1-B, which threads a balloon
catheter through the vasculature to the diseased site and inflates a balloon to compress the
plaque. The initial effects of this procedure are encouraging as flow is immediately restore,
but shortly after the vessel would restenosis or renarrow [6]. The next major breakthrough
was the incorporation of a stent or metal mesh work on top of the balloon catheter to
prop over the vessel, Figure 1-C. This permanent implant has improved upon the balloon
angioplasty procedure and prolonged patency, but still has led to a significant degree of
restenosis [7]. Researchers have added drugs like paclitaxel or rapamycin to the stent to
prevent restenosis. These drugs have helped reduced the restenosis rate, but have lead to
thrombosis at later time points from the lack of cellular infiltration [8, 7]. Ongoing research
is continuing to evaluate the ideal drug delivery rate and stent design [7].
The second major surgical option to treat CHD/PAD and the primary focus of this
dissertation is bypass surgery which diverts flow around the diseased location to restore
blood flow, Figure 1-D. This procedure is more invasive than the percutaneous route, but
is often required due to the advanced degree of atherosclerosis or widespread disease. The
autologous vessel is the current gold standard for the bypass surgery, but is often unavailable
due to widespread vascular disease [9]. The patency of the autologous vessel after bypass
surgery is often less than 50% at 9 years [10]. In order to improve upon this, the focus of






Figure 1: A) Atheroslcerotic vessel - showing plaque that is narrowing the lumen of the
vessel; B) balloon angioplasty - inflated balloon, which is compressing the plaque on the
vessel wall; C) stent deployment in an atherosclerotic vessel that has restored blood flow; D)
coronary artery bypass - vascular graft from the aorta to coronary to bypass the narrowed
artery in the heart.
1.4 Anatomy of the Blood Vessel
In order to create an autologous graft alternative, it is important to understand the
blood vessel anatomy. The blood vessel is broken up into three main parts the tunica
intima, tunica media, and tunica adventitia, Figure 2. The tunica intima is the inner most
layer of the blood vessel that primarily interacts with the blood and acts as a barrier to
prevent thrombosis. This layer is the thinnest of the three and is composed of a single
layer of endothelial cells. Moving to the middle part of the vessel, the tunica media is the
muscular and structural region that is responsible for dilation and constriction. This region
is made up of SMCs, connective tissue, and elastin. Vascular tone is modified by the SMC
response to various local or global stimuli. The outer most layer of the blood vessel, the
tunica adventitia, acts as a structural support and helps keep its shape. This portion of the





Figure 2: Anatomy of the blood vessel showing the three layers (inside to outside): tunica
intima, tunica media, and tunica adventitia. The tunica intima is composed of a single
layer of endothelial cells and acts as a barrier to prevent thrombosis. The tunica media
is composed of elastin and SMCs, which are responsible for dilation and constriction of the
vessel. The tunica adventitia is composed of connective tissue that helps to anchor the vessel
in place.
1.5 Atherosclerosis
Over time, the healthy blood vessel starts to age and disease can creep in. The most
common vascular disease is atherosclerosis or the deposition of fatty plaques on the vessel
wall, Figure 1-A. This disease can start in the first or second decade of life and progresses
throughout the lifespan of the person [11]. This disease starts from chronic damage to the
endothelial cells from hypertension, hyperlipidemia, smoking, and many other factors [12].
Continued damage to the endothelium results in endothelial dysfunction that increases the
permeability of the vessel and promote cellular adhesion. Luminal cells and SMCs from the
medial layer migrate to the intima layer and engulf the local lipids. These cells start to form
a fibrous lesion with a lipid core and over time these lesions or plaques become more complex
with calcification and ulcerated luminal surface. Eventually these lesions can become so long
and diffuse that blood flow in the vessel is limited or nonexistent which in turn could result
in a heart or stroke. These narrowed lesions are also at a high risk of clotting or thrombosis.
Hence, there is a need to treat these vessels and restore blood flow.
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1.6 Tissue Engineered Vascular Graft and Design
The tissue engineered vascular graft (TEVG) is an artificial blood vessel that can be
used to bypass the obstructed or narrowed blood vessel for CHD and PAD. The ideal TEVG
will be an acellular off-the-shelf implant that will remodel into a fully functional vessel
over time. The goal of the implant is to remain patent, promote cellular infiltration, and
encourage positive remodeling of the TEVG. Some key advantages of a TEVG are that it
can be tailored to the host in terms of mechanics and composition, allow drug delivery, and
not require a secondary surgical site, which is true for autologous vessel bypass grafting
[13, 14]. Achieving the ideal TEVG for small diameter (< 5 mm) applications has not yet
been achieved, likely due to graft design parameters including but not limited to material
choice, implantability, compliance, and antithrombogenicity [15, 16]. The need for a TEVG
still remains, however, as native vasculature, current gold standard, is often unavailable due
to widespread disease and in clinical applications where autologous grafts are not currently
in use (ateriovenous shunting).
The selection of materials in TEVG design plays a vital role in the success of the graft.
Native and synthetic polymers have often been the go-to choice for TEVG researchers
due to their mechanical properties, biocompatibility, degradability, and chemical versatil-
ity [17, 18, 19]. Early on, synthetic vascular grafts (DACRON or PTFE) gained traction
in the treatment of peripheral arterial disease but, these grafts have generally acted as a
mechanically strong inert material for blood to flow through rather than a medium that
promotes vessel remodeling. Other synthetic materials such as polycaprolactone (PCL) also
have a high mechanical strength, but can also degrade over time to allow for remodeling.
While a high concentration of PCL in the TEVG can be detrimental [20], balancing this
polymer with a natural biopolymer (e.g., gelatin). To make this PCL:gelatin TEVG im-
plantable, the graft must also include a cross-linking agent to prevent gelatin degradation.
Specifically, a cross-linking agent (e.g., UV light, glutaraldehyde, genipin) typically interacts
with free amine groups in the gelatin. Recently, genipin (extract from the gardenia fruit)
has become a preferred replacement for other cross-linking agents (glutaraldehyde [21]) as
it has been shown to reduce in vivo calcification, cytotoxicity, and increase the strength of
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the gelatin fibers [22, 23, 24, 25, 26]. Modulating gelatin degradation is also vital to drug
delivery from the TEVG. Previous work has demonstrated that increasing the gelatin con-
centration in TEVGs leads to an increased in vitro drug delivery of TGFβ2 release [27]. By
varying amount of gelatin and concentration of drug, one can potentially modulate cellular
and extracellular activity around/inside the implant. Incorporation of all of these factors
into a TEVG could improve the functional performance of the graft in small diameter appli-
cations. This work will look to further evaluate the affects of compliance and drug delivery
from an implanted TEVG.
1.7 Preclinical Analysis of TEVGs
Before moving to in vivo work, the researcher should perform some preliminary ex-
periments on the TEVG. These tests can consist of the following: suture retention, burst
pressure, mechanics, platelet adhesion, compliance, cytotoxicity, degradation, release profile,
in silico testing, and many more [13]. This work will help to elucidate how the construct will
perform in vivo and help the researcher narrow down their constrains. For this work, the
majority of the preliminary experiments were performed by Tamimi et al. and Ardila et al
[28, 29]. These studies demonstrated how compliance and TGFβ2 can be tuned in a TEVG
and this dissertation will further evaluate these concepts in an in vivo model.
Once preliminary work is complete, preclinical testing is the next step and is generally
performed in a small animal model, mouse or rat. These small animals provide a high
throughput model for initial formulation studies and can provide a large sample size [30].
For TEVG research, the rat model tends to be the animal of choice due to its slightly larger
vessel size and was selected for this dissertation [30]. The TEVG is most often implanted
into the rat abdominal aorta in line with blood flow with patency and cellular infiltration
as the assessed outcomes. Initial cellular infiltration into the scaffold can occur within days,
while full cellularization can take months depending on the scaffold design. The patency of
the graft is an indicator of success, but due to the differences in the clotting cascade of the
rat this model is limited and requires the use of a larger animal [31].
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Large animal models are often the next step after a successful small animal study. For
example, the new TEVG X showed excellent patency, positive graft remodeling (ECM dis-
position) and, cellular infiltration in the rat model. This data would suggest that a larger
animal model is warranted. The large animal model for the TEVG tends to the sheep or
porcine carotid or coronary due to similarities in clotting mechanisms, long length of implant,
and similarity to humans [30]. In this dissertation, we will look at future work using a pig
coronary to assess drug delivery using photoacoustic imaging and implant a sheep carotid
with a TEVG to evaluate the initial patency.
1.8 Hypotheses and Specific Aims
This dissertation has sought to further highlight the the affect TGFβ2 and compliance
has on TEVG design. The objective of this work was to quantify cell infiltration, cell
type, and extracellular matrix production while using ultrasound, photoacoustic imaging,
multiphoton microscopy, and histology. This research will lead to a better understanding
of how compliance positively affects TEVG remodeling, TGFβ2 affect on cells in vivo, and
promote noninvasive imaging in small animals. The objective above will be testing in the
following aims:
Hypothesis 1: Compliance-matched TEVGs will promote SMC infiltration and positive
remodeling of the TEVG compared to a hypocompliant graft in a rat aortic interpositional
implantation model.
Specific Aim 1: Determine the in vivo compliance, patency, cellular infiltration, and
extracellular matrix production of hypocompliant and compliance-matched TEVGs when
implanted in the aorta of Sprague Dawley rats (n=7) for 28 days. Rationale: Compliance
mismatch is known to be a cause for TEVG failure and our laboratory has the unique abil-
ity to modify these properties. Therefore, we will leverage this capability to quantify how
compliance alters the cellular infiltration of our TEVG.
Hypothesis 2: Release of transforming growth factor β2 (TGFβ2) from a TEVG pro-
motes acute cellular ingrowth in a rat aortic interpositional model.
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Specific Aim 2: Use immunofluorescence and second harmonic imaging to assess cell
infiltration and ECM remodeling of a TGFβ2 (0, 10, and 100 ng/mg) eluting hypocompliant
and compliance-match TEVG in the aorta of Sprague Dawley rat (n=3) following five days
of implantation. Immunofluoresence and two photon imaging will be used to evaluate the
cellular content, collagen, and elastin production in the explants. Rationale: Our prelimi-
nary data suggests that modulation of TGFβ2 can promote the migration and proliferation
of vascular smooth muscle cells (SMC) into a TEVG. We therefore believe that the addition
of TGFβ2 will promote cellullar ingrowth.
Hypothesis 3: Photoacoustic Imaging (PA) and spectroscopy can noninvasively quan-
tify the release of fluorescent molecules from vascular implants.
Specific Aim 3: Develop a Photoacoustic Imaging (PA) approach to quantify drug
surrogate concentrations in cardiovascular applications. PA imaging with spectral decom-
position will be used to differentiate drug surrogate concentration from porcine heart tissue
to quantify the delivery of a drug surrogate. Rationale: Imaging modalities with increased
depth of penetration will open new avenues of investigation for tracking the release of flu-
orescently labelled drugs and cytokines in animal models. This may be useful for future in
vivo or in situ assessment of the biodegradation and cytokine elution from our vascular graft.
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2.0 In-vivo assessment of a tissue engineered vascular graft computationally
optimized for target vessel compliance
For this aim, the effect of compliance on TEVG design was evaluated between two
hypocompliant and a compliance-matched grafts implanted in the abdominal aorta of a
Sprague Dawley rat. The compliance-matched constructs were modified by our laboratory’s
custom computational/experiential approach that varies composition. The two hypocompli-
ant grafts’ compliance were modified by either composition or increased crosslinking agent.
Cellular infiltration and extracellular component were evaluated at 28-days [32].
2.1 Introduction
Compliance mismatch is a common cause of TEVG failure and often overlooked in pre-
clinical design. [33, 34, 35]. The majority of TEVG tend to be hypocompliant or less
compliant than the target native vasculature [36, 37, 38, 39, 40, 41]. These hypocompliant
TEVG cause hemodynamic environmental changes or non-homeostatic mechanical strains
that result in the development of intimal hyperplasia, thrombus formation, and ultimately
graft failure [42, 43, 44, 34]. In this aim, we have developed a method to modify TEVG
compliance by composition and crosslinking concentration. The compliance of the TEVG
will be modified and evaluated using in vivo ultrasound and histology to demonstrate the
effects of compliance on vascular graft design.
2.2 Methods
2.2.1 TEVG Characterization and Fabrication
2.2.1.1 Preparation of Rat Aorta
All protocols were approved by the University of Pittsburgh Institutional Animal Care
and Use Committee. The infrarenal abdominal aorta of 13 male Sprague Dawley rats (175-
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225g) were extracted and any adventitial connective tissue was removed gently with forceps.
The aorta, 1.5 cm in length, was then placed in phosphate-buffered saline (PBS) pH 7.4
(Thermo Fisher Scientific, Waltham, MA) with 1% (v/v) Gibco Penicillin-Streptomycin
10,000 U/mL (Thermo Fisher) and 1% Gibco Amphotercin B (Thermo Fisher) for 24-48
hours post mortem at 4◦C before beginning of compliance testing to prevent contamination
of the tissue.
2.2.1.2 Compliance Testing
The compliance of rat aorta was tested using our custom microbiaxial optomechanical
device (MOD) [45, 46, 47, 48, 49, 50, 51]. This device has been extensively used in our
laboratory to mechanically characterize tubular and planar vascular tissues and biomaterials.
Briefly, each sample was cannulated on opposing ends using a 1 mm outer diameter (OD)
glass capillary, tied with suture, and sealed using super glue (Loctite). The cannulated
sample was then mounted inline within the MOD bath that was filled with saline, kept
at 37◦C. The arteries were preconditioned circumferentially (0 to 120 mmHg) and axially
stretched (15% strain) seven times prior to the collection of final diameter and pressure. The
outer diameter (OD) of each sample was measured using a digital camera as intraluminal





2.2.1.3 Compliance Matching and Computational Optimization Routine
Specific construct formulations were determined using our developed computational op-
timization routine [28, 52]. Previously, our research group has developed a finite element
optimization scheme (Figure 3A) to predict the thickness and Gelatin:PCL (G:P) ratio
of an alternating layered construct that matches the compliance and geometry of rat aorta
[28, 52]. Briefly, tubular TEVGs consisting of either 20G:80P, 50G:50P, and 80G:20P were
fabricated and tested using the MOD device. Each construct was pressurized from 0 to
120 mmHg at 0, 5, 10, and 15% axial strain. From this testing, the material constants
were collected from a Fung-type constitutive model and assign to gelatin and PCL, in silico.
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Next, a computational optimization scheme was used to determine the TEVG’s formulation
to match a specified compliance (hypocompliant or compliance-matched). For this study,
each construct consisted of 12 total layers with two alternating polymeric formulations. The
optimization scheme uses Matlab (MathWorks Inc, USA) to generate an input file for the
ABAQUS finite element solver (Dassault Systemes Simulia, France) which consisted of a four-
node, reduced-integration, axisymmetric finite element model that simulated the compliance
of the construct from 0 to 120 mmHg. For computational optimization, the constrained
parameters were the construct’s inner diameter, number of layers, and total thickness. The
open design parameters were the G:P ratio and the thickness of each of the paired layers. The
optimization function modified the open design parameters until the ABAQUS simulation
matched the specified target compliance to within 1%.
2.2.1.4 Electrospinning Materials and fabrication
All TEVGs were fabricated using an electrospinning process, crosslinked in genipin, and
tested for compliance. Polycaprolactone with a molecular weight 80,000 (Sigma-Aldrich,
St. Louis, MO) and gelatin extracted from porcine skin (Sigma-Aldrich) were dissolved in
1,1,1,3,3,3-hexafluoro-2-propanol (HFP) (Sigma-Aldrich) to create a 10% w/v solution. All
constructs were electrospun using IME technologies electrospinning device (Waalre, Nether-
lands). Briefly, electrospinning solutions were loaded into 5 ml BD syringes (BD Franklin
Lakes, NJ), placed in a computer-controlled syringe pump, and connected to 1mm PTFE tub-
ing. This setup was connected to a translating stage, 300 mm/s, and was expelled through
a 0.6 mm ID stainless steel tip at a working distance of 10 cm with a climate-controlled
chamber at 25◦C and 30% humidity. The polymeric solutions were dispensed at a rate of 50
µL/min onto a 1.1 mm diameter steel rod rotated at 300 rpm with a 15-kV voltage differ-
ence. The two polymer formulations were sequentially dispensed horizontally and vertically
(Figure 3B) from the IME electrospinning device which allowed for a multi-layer compo-
sition. During the electrospinning process, the syringe with the higher gelatin formulation
was spun from the vertical nozzle. It should also be noted that during the electrospinning
process, the user waited 4 minutes before starting the next layer. This waiting period allowed
the inline pressure to dissipate and extrude all the material. Once completed, HYPOpcl and
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CMgel were crosslinked in 0.5% (w/v) concentration of genipin (Wako Chemicals USA Inc,
USA) in 200 proof ethanol for 24 hours at 37◦C and shaken [28].
After crosslinking, half of the construct (1.5 cm) was compliance tested in our MOD
device to confirm the construct met the desired compliance. Details regarding compliance
testing are found in Section 2.2.1.2. Once confirmed, this half of the sample was embed-
ded in O.C.T. Compound (Thermo Fisher Scientific, USA), frozen, cross-sectioned (10 µm)
with Microm HM550 cryostat microtome (Thermo Fisher Scientific, USA), and imaged using
bright field microscopy. Three locations along the length of the sample were averaged to de-
termine the construct area, inner radius, and thickness using a Nikon 90i Eclipse fluorescence
microscope (Nikon USA, USA). If the tested sample met the desired compliance, the other
half of the sample (not tested) was implanted into the abdominal aorta of a Sprague Dawley
rat. The implant sample’s physical dimensions matched the test sample.
The formulations of the compliance-matched and hypocompliant (stiff) grafts were de-
termined using the optimization scheme detailed in Section 2.2.1.3. The compliance-
matched (CMgel) construct was compliance-matched to rat aorta with a high gelatin content
(layers composed of approximately 75G:25P and 50G:50P). The hypocompliant formation
(HYPOpcl) was composed of a high amount of PCL (layers composed of approximately
20G:80P and 35G:65P) and was targeted to 50% of the compliance value of the CMgel grafts.
This hypocompliant graft had a compliance similar to Dacron or ePTFE [53]. Both CMgel
and HYPOpcl grafts were crosslinked using 24 hours of 0.5% genipin. To further isolate the
effect of compliance in grafts with larger gelatin percentages, a third group was added to the
study - HYPOgen. For this formulation we initially tested the CMgel graft formulation in
0.5%, 1%, and 10% w/v genipin concentrations crosslinked for 24 hours at 37◦C and found
that the CMgel formulation had a compliance similar to HYPOpcl when crosslinked in 10%
w/v genipin. The hypocompliant construct was called HYPOgen and acted as another con-
trol group with a hypocompliant mechanical response, but with a gelatin content similar to
the CMgel group. The detailed construct formulations are provided in Table 1. Layers 1
and 2 (L1 and L2) are the repeating units of the grafts which total the 12 layers.
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Table 1: Polymeric formulations, layer thickness, and crosslinking concentrations for the







Individual Layer Thickness (µm)
Genipin Conc.
(w/v)L1 L2 Repeats (L1+L2) Total
HYPOpcl 20:80 35:65 8 5 6 78 0.5%
CMgel 75:25 50:50 8 5 6 78 0.5%
HYPOgen 75:25 50:50 8 5 6 78 10%
2.2.1.5 Suture Retention
The suture retention of each scaffold was determined using an in house custom made
uniaxial device. Electrospun tubular constructs (n=6) around 1 cm in length were clamped
distally in our uniaxial setup. A single 10-0 nylon (AROSurgical) suture was used to create
a single loop approximately 2 mm away from the scaffold’s proximal end. The free ends of
the suture were secured to the upper clamp and any excess slack removed from the suture.
The sample was then pulled at a rate of 2 mm/min until the suture tore out of the sample.
The load displacement curve was used to determine the maximum force each sample held.
Differences between groups were compared using a Kruskal-Wallis test.
2.2.1.6 Burst Pressure
Burst pressure of each scaffold (n=5) was quantified by increasing intraluminal pressure
until catastrophic rupture occurred. For each test, the construct was cannulated on both
sides with one end connected to a syringe pump (Harvard Apparatus, Holliston, MA) and
the other clamped to form a closed loop. Saline was injected into the construct at 50 mL/min
until failure. The maximum pressure (Weiss gauge, 0-60 psi) was recorded before failure and
taken to be the burst pressure. Statistical differences between groups were first check for
normality, transformed using a Box Cox, and compared using Kruskal-Wallis ANOVA with
a Tukey post hoc.
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2.2.1.7 Cytotoxicity
Each scaffold’s degradation product was evaluated for cytotoxicity using rat aorta smooth
muscle cells (RSMC (Lonza)) following closely the methods of Guan et al [54]. Cells were
seeded at a density of 4.0 x 104 onto a 24-well tissue culture plate. Eluent from each
construct (n=5, 8 mm in length) soaked in PBS for 24 hours was added to each well at 1:10
ratio (eluent:media). The positive control was sterile PBS:media (no degradation products).
Cell viability was measured with an MTS assay (Promega) at 48 and 96 hours with media
changes occurring ever 48 hours. For the MTS assay, 20µL of MTS solution was added per
100 µL media to each well, incubated for 2.5 hours, and the absorbance at 490 nm was
recorded to determine cell viability. Results were compared to the control using a two way
ANOVA and normalized.
2.2.2 Rat Implantation
2.2.2.1 Rat Interpositional Abdominal Aorta Surgery
TEVGs were implanted into the abdominal aorta of 8-week-old male and female Sprague
Dawley rats (total M and F 11 and 10, respectively) and weighed on average (203±37 g)
with n=7 for each group. Male and female rats were chosen in order to present results more
broadly applicable to the rat population. For each surgery, the rat was anesthetized with
isoflurane (3% for induction and 1% for maintenance). An abdominal medial incision (3-4
cm) was made using No. 10 scalpel. The small intestine and the cecum were extracted from
the abdominal cavity, retracted to right upper quadrant, and covered with wet gauze. The
abdominal aorta was dissected, isolated (1 cm portion above the aortic bifurcation), and
generally 1-2 branches of the aorta were ligated and transected. About 1 ml of heparin was
administered on the small intestine and into the abdominal cavity to prevent clotting. Two
30 g clips were applied at the iliolumbar artery and the bifurcation to prevent blood flow.
The aorta was transected at the center and each lumen was irrigated by saline. For the
anastomosis, it was initiated on the proximal vessel with stay sutures, 10-0 nylon, placed
at the 3 and 9 o’clock positions. After placing 3-4 stitches on the anterior wall, the vessel
was rotated 180o clockwise to expose the posterior wall and 3-4 stitches were placed on the
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posterior wall. This same procedure was performed on the distal location. Before the last
suture was tied the lumen was irrigated and then the clips were removed. If oozing occurred,
pressure was applied gently on the suture line which generally allowed for hemostasis. On
some occasions an extra stitch was added when blood leakage was unable to be stopped. Each
anastomosis had between 7-10 stitches per end with the average implant length consisting of
5.7±1.1 mm which is shown is Figure 3C. Blood flow was assessed by performing a patency
test. Once complete, the small intestine and cecum were returned into the abdominal cavity.
The rectus abdominis was closed with an interrupted 4-0 absorbable polyfilament suture, the
skin was closed with buried 5-0 nylon suture, and the skin was stapled (to prevent the animals
from chewing out their stitches). The average surgery time was around 1.75 hours with the
anastomoses taking about 50 minutes. One animal in the CMgel group was excluded from
the study due to an unrelated death within the first three days. All other animals survived
the duration of the study with little to no discomfort.
In days 1 to 3 post operatively, each rat received 0.5 mg/kg buprenorphine and 10 mg/kg
cefuroxime intramuscularly twice a day to minimize pain and prevent bacterial infections,
respectively. Carprofen (5 mg/kg) was also given at 24 and 48 hours post operatively to min-
imize inflammation. For solid medications, aspirin (pain reliever) and dipyridamole (blood
thinner), were ground up with a mortar and pestle and mixed with jelly inside a miniature
ice cream cone which also acts as another enrichment object for the animal. For the first
week aspirin and dipyridamole were given to the rat at a concentration of 200 mg/kg and
250 mg/kg and decreased at weeks 2-4 to 100 mg/kg and 100 mg/kg, respectively. After 4
weeks, the rats were euthanized with carbon dioxide inhalation and cervical dislocation, the
explant was recovered and place in 4% paraformaldehyde solution in PBS (Thermo Fisher
Scientific, Waltham, MA), and later sectioned.
2.2.3 Graft Measurements and Quantification
2.2.3.1 In-vivo Ultrasound
High frequency Doppler ultrasound was used to evaluate graft patency, diameter, com-








































Figure 3: A) Overview of the optimization routine that demonstrates how mechanical test-
ing of the vascular grafts lead to a computational optimizational scheme to calculate graft
formulation; B) Electrospinning setup, demonstrating the two-nozzle setup of the device; C)
Implantation of a CMgel TEVG in the abdominal rat aorta.
2100 (FUJIFILM VisualSonics Inc, Canada) with a 30 MHz probe. In-vivo measurements
were taken for each animal up to a week before surgery and at one, two, and four weeks
post-implantation. It should be noted, that the VEVO 2100 was located in another facility
which prevented immediate imaging post implantation. To collect the ultrasound data, the
rat was anesthetized with isoflurane (3% for induction and 1% for maintenance), abdominal
fur was removed using Nair Hair removal (Church & Dwight), applied ultrasound gel, and
imaged. Cross-sectional in-vivo imaging was used to determine the aorta’s location. Once
located, the implant was imaged longitudinally. Patency was defined as an observable blood
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flow under ultrasound imaging. Any nonpatent vessel was excluded from subsequent sta-
tistical analysis. At each time point, the maximum and minimum diameter of the implant
was recorded over one cardiac cycle to determine the implant’s average inner diameter and
compliance using Equation 2.1. The average maximum velocity inside the implant was
recorded using Doppler ultrasound and all measurements were taken inside the implant. All
collected data was processed using the Vevo Lab software version 1.7.1 and adjusted for the
probe angle using the approach described in Park et al. [55].
2.2.3.2 Preparation, Immunohistochemistry, and Fluorescent Imaging
The proximal and middle locations of each TEVG was evaluated for cell infiltration
using immunohistochemistry. Each fixed sample was cut in the middle and separated into
proximal and middle sections, frozen in O.C.T. medium, and kept at -80◦C. All samples were
sectioned at 10 µm using a Microm HM550 cryostat microtome. The middle samples were
cut cross-sectionally while the proximal sections were cut longitudinally.
For immunohistochemistry, samples were rehydrated in PBS and soaked in 1% sodium
dodecyl sulfate (Sigma-Aldrich, St. Louis, MO) in PBS for 15 minutes. The samples were
next permeabilized in 0.3% triton X-100 (Sigma-Aldrich) for 15 minutes and blocked with
0.5% bovine serum albumin (Sigma-Aldrich), 0.3M glycine (Thermo Fisher Scientific), and
20% goat serum (Thermo Fisher Scientific) for one hour. Following blocking, all samples
were incubated with a primary antibody over night at 4◦C. α-Smooth muscle actin (αSMA,
1:100, Abcam), calponin (CAL, 1:100, Abcam) and smooth muscle myosin heavy chain
(MHC, 1:100, Abcam) were used to detect smooth muscle cells. Ki67 was used to detect
highly proliferative cells, thus acting as a surrogate for increased risk of intimal hyperpla-
sia. Endothelial cells were detected using CD31 (1:100, Abcam) and macrophages using
CD68 (1:100, Abcam), CD86 (1:100, abcam), and CD163 (1:100, Abcam), for inflammatory
response, M1, and M2 macrophage phenotype, respectively. Elastin in the implant was de-
tected using elastin Alexa Fluor antibody (Santa Cruz Biotechnology, Inc) which did not
require a secondary antibody. After incubation and washing, the samples were incubated for
1 hour at room temperature with Alexa Fluor 488 Goat Anti-Rabbit IgG (Abcam, 1:1000)
except for αSMA which was incubated with Alexa Fluor 488 Donkey anti-goat IgG (Abcam,
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1:1000). Each sample was then washed and counterstained with DAPI mounting medium
(Abcam).
Each marker was imaged using the Nikon 90i Eclipse fluorescence microscope. Briefly,
full mosaic images of each entire sample were taken in the DAPI (excitation at 359 nm;
emission at 461), FITC (excitation at 495 nm; emission at 519 nm), and Cy5 (excitation at
647; emission at 665) emission channels using a Nikon Plan Apo 10x/0.45 objective. The
DAPI channel was used to identify cell nuclei, Cy5 was autofluorescence from the genipin
crosslinking/implant, and FITC was the marker of interest. It should be noted that the FITC
channel exposure time was consistent between each marker so that quantitative analysis could
be performed.
2.2.3.3 Multiphoton Imaging
Multiphoton microscopy was performed on the Pitt Advanced Intravital Microscope at
the University of Pittsburgh and used to evaluate collagen deposition within the implant
(cross-sectionally and longitudinally). In this setup an Olympus BX51 upright scanning mi-
croscope (Olympus, Tokyo, Japan) was coupled into a 120-fs tunable pulsed laser (INSIGHT
DS+DUAL, Newport, Irving CA) and Olympus XLUMPLFL 20x water emersion objective
(NA 0.9). The second harmonic generation (SHG) signal of fibrillar collagen was imaged
using an excitation of 780 nm and a collection of 377/50 nm. DAPI and autofluorescence
was also imaged at 780 nm with a power of 25-31 mW and collected with 525/50 nm and
620/60 nm bandpass filter, respectively. The signal was collected over multiple 499 x 499 µm
fields of view with a 5 µm z-step-size through the thickness of the sample. Montage slices of
each channel (377, 525, and 620 nm) were converted into maximum intensity projection and
used for image quantification.
The percent construct remaining, cells signal inside the construct, and collagen through-
out the construct were quantified from each image. Bright field images before implantation
(see Section 2.2.1.4) and multiphoton images of the explant were used to calculate the
percent construct remaining: ((TEV Goriginal − TEV Gexplanted)/TEV Goriginal) ∗ 100. For
cells inside the construct, ImageJ (Fiji) was used to isolate the cells inside the construct
which were counted using the analysis particle function. The percent collagen throughout
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the construct was determined similarly to antibody image processing and is described in
Section 3.2.4.4.
2.2.3.4 Image Processing
Cellular and extracellular markers were evaluated using Matlab image processing to
determine differences between groups. It should be noted that the FITC channel was changed
to red and the Cy5 to green color. Following faux coloring, all data sets had 3 channels which
were as follows: cell nuclei channel (blue), implant channel (green), and antibody or collagen
channel (red). Each antibody channel was sampled and then binarized to identify the signal
of interest and remove noise. The implant channel was used to separate antibody signal
into three regions: lumen, graft, and abluminal. The lumen region was designated as the
section from the inner boundary of the implant to the lumen. The graft and abluminal
regions were composed of the inside or outside the implant, respectively. The area of the
abluminal region was limited to a 25% increase of the exterior diameter of the implant. To
calculate the amount of signal per antibody in a certain region, the total number of antibody
pixels was divided by the total number of the section’s pixels (lumen, graft, or abluminal).
For the cross-sectional samples, the whole implant was used for each sample and averaged
among all rats in the specific group. The ratio of CD163 to CD68 signal was also evaluated
during this process to help identify differences in macrophage phenotype. The cross-sectional
samples were also used to calculate the percent endothelialization and luminal thickness. For
percent endothelialization, the CD31 signal length was divided by the lumen circumference
and multiplied by 100. For luminal thickness, each sample was measured at 4 locations
and evaluated for significant differences using a Box Cox transformation and a mixed effect
model.
In the longitudinal sections, the first proximal 150 µm (lumen, graft, or abluminal) was
processed as described in the paragraph above. The 150 µm portion was selected as this was
the shortest segment of the longitudinal samples that were imaged for all groups. The sample
size for the longitudinal samples was n=4 due to initial processing. Luminal thickness was
measured three times along the length of the image and averaged.
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2.2.3.5 Statistical Analysis
Sex differences were assessed using a paired t-test, however no differences were found and
as such gender was not carried through subsequent statistical analysis. After processing, the
samples were checked for normality and nonnormal data was transformed using a Box Cox
transformation. A linear mixed effect model with a Tukey post hoc was used to statistically
analyze how each outcome was influenced by graft type at a specific region in the proximal
or middle location. The random effect was the sample and the fixed effects were graft type
and region (lumen, graft, and abluminal). The total implant results were evaluated using
an ANOVA or Krustal Wallis with a Tukey or Dunn post hoc depending on the normality
of the sample.
Preliminary work using αSMA marker was used to determine the sample size for each
group in the study. Specifically, a power analysis was calculated using an alpha of 0.05 and
a power of 80%.
2.3 Results
2.3.1 Construct Characterization
Pre-implantation compliance, thickness, and inner diameter using bright field microscopy
are shown in Figure 4. The HYPOgen and HYPOpcl constructs pre-implantation were found
to be stiffer than those in the CMgel (p<0.05) group and there was no gross delamination
between electrospun layers in any construct. The average thickness of each construct was
104.2±15.9, 88.35±11.1, and 114.4±10.1 µm for the HYPOpcl, CMgel, and HYPOgen groups,
respectively. The HYPOgen group was thicker than CMgel,(p = 0.03) suggesting that genipin
was the cause of the increase. The inner radius of the construct was not found to be statis-
tically different across groups. The results of this testing confirmed the desired compliance
of our constructs.
The suture retention for HYPOpcl, CMgel, and HYPOgen groups was 43.47, 10.83, and
13.22 g, respectively. The burst pressure for HYPOpcl, CMgel, and HYPOgen groups were
1435, 504, and 497 mmHg, respectively. The suture retention and burst pressure for the
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HYPOpcl group was greatly increased compared to CMgel and HYPOgen with only HYPOgen
to HYPOpcl burst pressure not found to be significant, p<0.05.
The cytotoxicity from genipin in each construct was tested by evaluating the degradation
products at 24 hours. The CMgel and HYPOgen showed a slight reduction in cell number
at 48 hours and no differences occured between the experimental groups and the positive




































































































































































Figure 4: Pre-implantation images, compliance, thickness, inner radius, suture retention,
burst pressure, and cytotoxicity of the HYPOpcl, CMgel, and HYPOgen TEVGs. The scale
bar is 50 µm. The compliance of the CMgel constructs matched rat aorta, while the HYPO
grafts were over twice as stiff. HYPOgen TEVGs were found to be slightly thicker than the
CMgel. All constructs had a similar inner radius, around 550 µm. The suture retention and
burst pressure of the HYPOpcl was greatly increased compared to the CMgel, and HYPOgen
TEVGs. The CMgel and HYPOgen TEVGs had a slight reduction of cell number at 48 hours
and no differences at 96, while the HYPOpcl had no differences at both time points. ∗,
p<0.05
21
2.3.2 Rat in-vivo Ultrasound
The in vivo ultrasound results demonstrated that HYPOpcl, CMgel, and HYPOgel grafts
had a patency rate of 6/7, 5/7, and 6/7, respectively. These results were subsequently
confirmed by histological analysis. The ultrasound sample size for each group was at least
n=3 for each time point with an exception of the CMgel group having an n=2 at the 2 and
4 weeks. The CMgel group had a similar compliance to rat aorta throughout the study. In-
vivo compliance measurements demonstrated that our mechanically optimized graft (CMgel)
remained compliance-matched throughout the implant period, while one or both of the
HYPO (stiffer) grafts demonstrated significant reductions in compliance compared to CMgel
at 2 and HYPOgel 4 weeks (Figure 5). Ex-vivo analysis of compliance was unable to be
conducted due to the limited amount of sample remaining from IHC. The average diameter
of the implants stayed relatively constant and similar to rat aorta throughout the study. The
only notable difference in diameter between groups occurred at the 4-week time point where
two HYPOgen grafts showed an increase in construct diameter, however this result was not
statistically significant.
The average maximum velocities of the HYPO grafts at two weeks was different that
rat aorta, p<0.05 Figure 5. There was also was a decrease in blood velocity for HYPOgen
grafts from 1 week to 2 and 4 weeks (p<0.05). We attributed the decrease in velocity in the
HYPOgen grafts to 2 graft dilations.
2.3.3 Multiphoton Imaging
The results of construct degradation, cellular infiltration, and luminal thickness using
multiphoton imaging are shown in Figure 6. More degradation (∼70%) occurred in the
CMgel and HYPOgen compared to the HYPOpcl constructs (∼30%). This high degradation
rate led to an increase in cellular infiltration with more cells in the HYPOgen vs. HYPOpcl,














































































HYPOpcl CMgel HYPOgen Rat Aorta S.D.
Figure 5: In vivo ultrasound measurements of compliance, average inner diameter, and
velocity in the HYPOpcl, CMgel, and HYPOgen TEVGs. The CMgel constructs matched
native rat aorta compliance over time, while the HYPO grafts were generally less compliant.
The average diameter stayed relatively consist over the one-month time point except for
the HYPOgen TEVGs that had two graft dilations. The average velocity for the CMgel and
HYPOgen TEVGs tended to decrease over the implantation period and the HYPOpcl TEVGs
stayed consistently below native rat aorta velocity. ∗, p<0.05, ∗∗, p<0.01
2.3.4 Quantitative Immunohistochemistry
Representative fluorescent images of both the cross-sectional middle and longitudinal
proximal locations of our TEVG are shown in Figure 7, Figure 8 and Figure 9, respec-
tively. The green and blue regions in these images represent the construct and cell nuclei,
respectively. Figure 7 shows representative cross-sectional images of the image with the
specific marker in red (αSMA, CAL, MHC, Ki67, CD68, CD163, CD86, and elastin). These
markers were quantitatively assessed using image processing in Matlab and the results are
shown in Figure 8, and Figure 9.
In the middle location, all regions (lumen, graft, and abluminal) and the total αSMA
signal were found to be higher in the HYPOgen & CMgel vs. HYPOpcl groups (p<0.05). For
the proximal location (Figure 8), there were no αSMA signal differences between the grafts







































































































Figure 6: Top) Cross-sectional multiphoton implant images of HYPOpcl, CMgel, and
HYPOgen TEVGs; Green, blue, and red represent the implant, cell nuclei, collagen, respec-
tively; The scale bar is 50 µm. Bottom) Differences in the amount of construct remaining,
cells inside our TEVGs, and luminal thickness. The HYPOpcl TEVGs had less construct
degradation and cellular infiltration than compared to CMgel and HYPOgen TEVGs. The
average luminal thickness was found to be similar between all implants. ∗, p<0.05
The proximal location of the implants displayed an increase in the more phenotypic
SMC markers CAL & MHC for compliance-matched TEVGs compared to either of the
HYPO constructs (Figure 8). In particular, we observed an elevation in total CAL signal
in the CMgel constructs compared to either of the HYPO formulations. This elevation was
similar to an increase in MHC in our compliance-matched TEVGs compared to both HYPO
grafts when quantifying signal within the graft itself. These phenotypic SMC differences
between graft type were not observed in the middle location of our TEVGs (Figure 9).
The total Ki67 signal in the middle location of all grafts was increased in HYPOgen vs.









Figure 7: Representative middle cross-sectional immunofluorescence images. Green, blue,
and red represent the implant, cell nuclei, and marker, respectively. The scale bar is 50 µm.
increased for HYPOgen vs. HYPOpcl in the lumen and abluminal regions, p<0.05. In the
proximal location, there was increased Ki67 in the graft region for CMgel vs. HYPOgen,
p<0.05. The middle location of all TEVGs displayed the only statistically significant
differences in macrophage content between graft type (Figure 9). There was an elevation
in the total CD163 signal in the CMgel and HYPOgen groups vs. HYPOpcl group (p<0.05
for CMgel vs. HYPOpcl comparison). These results generated an increase in the total ratio
of pro-remodeling macrophages to pan (CD163/CD68) in the CMgel and HYPOgen TEVGs
(p<0.05). The CD86 signal was generally decreased in the HYPOgen with differences when
compared to lumen HYPOpcl, abluminal CMgel, and total CMgel in the middle location.
Endothelialization of the constructs were evaluated using marker CD31 and only at the
middle location of the construct. The percent endothelialization was found to be 48±30%,
15±10%, and 34±24% for the HYPOpcl, CMgel, and the HYPOgen TEVGs, respectively. The
total collagen content had no significant differences occurring in either location however there
were regional differences. The lumen and graft regions in the middle location of CMgel grafts
had a significantly increased amount of collagen than either hypocompliant grafts, Figure































































































Figure 8: Representative proximal longitudinal immunofluorescence images (top). Immuno-
histochemistry quantification of signal in the lumen, graft, and abluminal regions for SMCs,
Ki67 cells, pan macrophages (CD68), M2 (CD163), M1 (CD86), M2/Total (CD163/CD68),
collagen, and elastin (bottom). SMC markers, MHC and Calponin, were relatively in-
creased in the CMgel compared to the HYPO groups. The Ki67 signal was elevated in
the graft region of the CMgel to the HYPOgel. The collagen produced was increased in
the lumen region of the HYPOpcl compared to CMgel group. ∗ = p<0.05; ∗∗ = p<0.01;























































































































Figure 9: Representative middle cross-sectional immunofluorescence images (top). Immuno-
histochemistry quantification of signal in the lumen, graft, and abluminal regions for SMCs,
Ki67 cells, pan macrophages (CD68), M2 (CD163), M1 (CD86), M2/Total (CD163/68), col-
lagen, and elastin (bottom). The αSMC in the CMgel and HYPOgen TEVGs was increased
compared to the HYPOpcl TEVGs. The Ki67, CD163, and elastin signal was elevated in the
HYPOgen compared to HYPOpcl TEVG. There was a luminal increased in CD163 and elastin
signal in the CMgel to HYPOpcl groups. CD68 signal was only evaluated in the abluminal
region of the HYPOgen compared to CMgel. The total and abluminal CD86 signal in the
CMgel was increased compared to the HYPOgen and the HYPOpcl in the lumen was increased
compared to the HYPOgen. The ratio of CD163/CD68 was increased in the CMgel compared
to the HYPO group. The collagen content in the lumen and graft of the CMgel were higher
than the HYPOpcl. ∗ = p<0.05; ∗∗ = p<0.01; Y axis = Pixels of Interest/Total Pixels;
Scale bar is 100 µm
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proximal location. The middle location generally was found to have more elastin in the high
gelatin groups (CMgel and HYPOgen) with differences occurring in the HYPOgen to HYPOpcl
in all regions/total and CMgel to HYPOpcl.
2.4 Discussion
Our results suggest that a TEVG computationally optimized for compliance matching
displays improved acute (28 day) in-vivo graft remodeling. Overall, the high gelatin groups
(HYPOgen & CMgel) degraded more quickly in-vivo thus allowing an increased cell infil-
tration into the constructs. Compliance matching the TEVG lead to quicker and more
mature phenotypic SMCs in the proximal location. The mechanical stimulus provided by
the compliance-matched constructs also demonstrated a more favorable cellular environ-
ment with increased collagen production in the middle location in the lumen and graft
regions. Hypocompliant TEVGs promote an elevated CD68 and CD163 response compared
to compliance-matched grafts, suggesting a more pro-inflammatory environment. These re-
sults along with desirable improvements in SMC phenotype demonstrate that tuning the
compliance of a tissue engineered vascular graft improves the in-vivo remodeling of a layered
TEVG over an acute 1-month implantation period.
From our immunohistochemistry results and the literature, compliance has consistently
been shown to affect SMC phenotype [56, 57]. In this study, there were increases in CAL
(mid-differentiated) and elevated trends in MHC signal (late differentiated) in the proximal
location of our compliance-matched grafts. This suggests that the mechanical environment
provided by compliance-matched grafts encourages SMCs to move towards a more contractile
phenotype earlier. Past in-vitro work by Bingcheng et al. is in agreement with our work as
they showed similar changes in SMC phenotype as the compliance of their electrospun grafts
increased [57]. Additional time points and explant functional testing (e.g., vasoreactivity)
will be necessary to determine if the observed results here continue to promote a more
functional vessel as our TEVG continues to be replaced by native host cells and extracellular
matrix.
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Likely due to our limited implantation time point, the middle of our graft showed slower
cell infiltration and a less differentiated SMC phenotype. This is consistent with the presence
of an increased number of αSMA positive cells in this region [58]. These results suggest
that gelatin is ideal for fast degradation and cellular infiltration which is similar to what
other groups have shown in-vitro [59, 60]. For the rat model, a higher gelatin content
graft appears to be ideal for promoting increased cell infiltration and migration, but as you
move to other animals there may be a need to balance this aspect. Generally, other animal
models may require varying lengths of time for cellularization and therefore may need a
slower degrading graft. Finding the ideal balance between the degradation of the scaffold
and cellular infiltration will be vital for a particular animal model. For example, a longer
implant in a sheep model will take more time to cellularize than a rat implant and this
should be taken into account. It should be noted that increasing the gelatin content beyond
what was used in this manuscript (a hypercompliant group) led to an even lower suture
retention than HYPOgen & CMgel, Figure 4, and an inability to implant the resulting graft.
The HYPOgen and CMgel were found to be slightly more challenging to implant than the
HYPOpcl grafts as a result of the lower suture strength.
SMC phenotype and functional behavior is also influenced by the local mechanical envi-
ronment and composition of the extracellular matrix surrounding these cells. Several groups
have shown that SMCs tend to migrate faster on surface coatings with stiffer substrates
[61, 62]. Substrate stiffness has also been cited as being able to change SMCs from a con-
tractile to a more proliferative phenotype[63]. We initially attributed our SMC results in the
HYPOgen group in the middle location to substrate stiffness. However, the HYPOgen group
had more highly proliferative cells (Ki67) in the total region than both low genipin concen-
tration groups (HYPOpcl & CMgel, p=0.09), suggesting that increased genipin concentration
may be the cause rather than compliance. This increase in highly proliferative cells suggests
that the 20x fold increase (22 to 440mM) of genipin between groups could be potentially
disruptive in-vivo. Genipin has been cited as a less cytotoxic agent than glutaraldehyde
in the literature, however elevated genipin media concentration (>10mM) can prevent cell
proliferation and promote cell death [64, 65].
While our TEVGs were fabricated with genipin concentrations near or exceeding these
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levels, our preliminary data suggests that the degradation products of our graft have little
to no affect on RSMC growth, Figure 4. This is likely due to the fact that our grafts were
thoroughly washed prior to implantation and as such do not expose the cells to these higher
concentrations of genipin. It also should be noted that we did see an increase of Ki67 signal
in the proximal graft region for the CMgel grafts compared to HYPOgen, however the specific
cause is unclear and will require future investigation.
General SMC alignment and distribution at either location was not able to be evaluated
due to the acute nature of the study, however our histological images show a grouping of
SMCs which is encouraging. We would expect to see increased TEVG remodeling and SMC
alignment at longer implantation time points and hope to evaluate this in the future studies
[66, 67, 68].
Macrophage infiltration and proliferation in the TEVG are vital to healthy graft remod-
eling and this varied in the proximal and middle location. Again, we saw signs suggesting
early cellular infiltration in the proximal anastomosis and generalized macrophage infiltration
occurring in the middle location. Specifically, there was a decrease in CD68 macrophages
in the abluminal region for compliance-matched constructs compared to HYPOgen. For the
higher gelatin grafts (HYPOgen & CMgel) there was an increasing trend of total CD163 which
may suggest that the presence of gelatin leads to a more pro-ECM maintenance and healing
response. This M2 response is generally correlated with extracellular matrix formation and
collagen production, which we found to be significantly higher in the compliance-matched
group in the middle location of in the lumen and graft regions (Figure 9). On the other
hand, the stiff constructs generally showed a decreased trend in CD163/CD68 compared
to compliance-matched grafts suggesting local mechanical response could be vital to tissue
regeneration. This also demonstrated that matching compliance of the vessel can provide
a favorable environment for extracellular matrix formation. Looking more specifically at
M1 macrophage markers (CD86), the HYPOgen group showed a general reduction in signal
compared to HYPOpcl and CMgel. These results suggest that higher genipin concentra-
tions could have an effect on reducing the M1 macrophage population. Genipin, specifically,
has been shown to reduce M1 macrophages in liver crosslinked samples when compared to
glutaraldehyde [69]. For CD68, it was generally increased in grafts with high PCL concen-
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trations (similar to our HYPOpcl group) [40, 70]. Here we demonstrate that similar levels
of CD68 and CD163 are elicited in grafts with half as much PCL, suggesting that the local
biomechanical environment may also contribute to this response.
Another important factor in the formation of a functional TEVG is the replacement of
our graft materials with the production of extracellular matrix, in particular collagen and
elastin. For collagen at the one month time point, the CMgel grafts generally had an elevated
signal in the middle location of the lumen and graft regions compared to the HYPO grafts.
These results suggest that compliance matching a graft can promote constructive in-vivo
remodeling. One unexpected result was the increase in collagen in the lumen of the proximal
location of the HYPOpcl grafts. The cause and implications of this result, along with the
general elevation of M1 macrophages in that area seems to suggest the start of intimal
hyperplasia [71, 72] but, this results will need to be studied in more depth at longer time
points to confirm. For elastin, CMgel and HYPOgen both had elevated signal in the middle
location of our grafts. These results suggest that higher gelatin content is more favorable for
elastin formation than PCL. Finding the right balance between the production of collagen
and elastin as our graft degrades will be important in maintaining the compliance of our
graft as it continues to degrade over longer time points. Future research will be needed to
determine the optimal rates.
An interesting trend from our study was the endothelialization of our grafts. We found
that both stiff grafts had an increased percentage of endothelialization compared to the
compliance-matched graft. This indicates that endothelial cells migrated more quickly onto
our hypocompliant grafts [58], which is consistent with literature indicating cells migrate
further and faster on stiffer substrates [73, 74]. This finding is contrary to our initial hy-
pothesis (that compliance matching may promote endothelialization), however this result
can be leveraged in future graft designs. For example, a graft with a very thin but stiff
inner layer could help promote early endothelialization while still maintaining optimal com-
pliance. In general, percent endothelialization in our study was similar to the literature at
one month, as complete coverage of grafts in the literature typically occurs around 3 months
post implantation [75, 68, 70, 76].
The primary goal of this study was to evaluate the influence of compliance and remod-
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eling on TEVG design. Our ultrasound data (Figure 5) showed that the CMgel constructs
stayed compliance-matched throughout the time course of the study. Maintaining compli-
ance demonstrated that the mechanical stimulus provided by the environment on cellular
infiltration was maintained and this has not been previously shown using a rat model. Most
TEVGs tend to be hypocompliant before implantation and maintain their compliance in-vivo,
however some groups have shown that compliance can vary over the course of remodeling.
Wu and Allen have demonstrated that a stiff or hypocompliant graft can remodel in-vivo
to increase compliance by 3 months and maintain compliance over time but still showed a
decreased stiffness trend compared to rat aorta [77, 66]. Another group also demonstrated
that a Poly(l-lactide-co-ε-caprolactone) TEVG increased in compliance for up to 12 months
[36]. From the quantification of cellular markers and extracellular matrix formation, these
previous studies demonstrate that graft degradation/remodeling can occur and transition a
degrading graft towards a functional vessel. In this study, the gelatin grafts (HYPOgen &
CMgel) also had a high percent of degradation and evidence of remodeling (collagen content),
however a unique feature of our graphs was their ability to maintain compliance throughout
the study and increase cellular infiltration in the gelatin groups. Looking more specifically
at degradation and cellular infiltration, our group has demonstrated that cellular infiltration
and degradation can be varied depending on composition/cross-linking and this is useful for
translating the results into larger animal models where varied cellular infiltration rates will
be necessary.
The patency rate of our HYPOpcl, CMgel, and HYPOgen grafts were 6/7, 5/7, and 6/7,
respectively, leading to an overall patency rate of 81%. This is similar to several studies in
the literature [39, 75, 78, 79, 80]. For example, Wu et al. has shown a similar patency rate
in their acellular TEVG with 17/21 remaining patent out to 3 months [77]. Nieponice et
al. showed lower patency rates for poly-(ester urethane) thermally-induced phase separation
scaffolds with 53% at 8 weeks and Pektok showed 100% patency through 24 weeks using a
PCL electrospun scaffold [81, 82]. While these results are encouraging, patency of our graft
could be further improved in the future with the incorporation of cells and/or surface coating
to reduce thrombogenicity [83].
The blood velocity results of our TEVGs were found to be relatively consistent with the
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current literature values, around 900 mm/s [78]. There were some graft dilations in HYPOgen
group at 2 and 4 weeks,(Figure 5), and these increases could be the onset of graft failure
or aneurysm in future time points. An unexpected result was the lack of a decrease in blood
velocity when comparing the HYPO to CMgel groups. This may be attributed to the short
implant period and the dilations seen in the a few of the HYPOgen grafts.
There are several limitations in this study. Rat aortic interpositional implantations offer
significant advantages including their use as a relatively high throughput model. However,
this model is limited as it has major differences in the hemodynamics, regenerative ability,
and physiology in comparison to target vessels in most human vascular diseases. In order to
minimize some of these limitations, other groups have used the rat carotid which has more
clinically relevant flow and a smaller diameter, but may still suffer from some physiological
differences [40]. Future implantations should consider utilization of an animal model with a
hemodynamic flow environment more similar to that in the target human vessel. The second
major limitation of this study was the acute one-month implantation period which restricts
the conclusions that can be made on long-term cellular infiltration and vessel functional-
ity. The earlier time point used here did however serve to identify differences in the acute
remodeling of our grafts. Our group is currently planning to investigate how the results
and conclusions presented here are altered in longer (3 to 12 months) implantation periods.
Another limitation was the range of materials selected to tune the compliance and thickness
of our graft to that of a rat aorta. These constraints limited the ability to increase suture
retention and burst pressure, as seen in the CMgel and HYPOpcl groups. Selecting different
materials or increasing the thickness of the implant could help prevent these problems in the
future. Finally, it should be noted that while compliance was controlled by manipulating
both graft composition and genipin concentration, this approach does present a confounding
factor within each group comparison. The authors of this manuscript want to emphasize
that conclusions made about compliance should only be made when both HYPO groups
have similar results and the compliance-matched group, CMgel, differs significantly from
these groups. If the reader is only comparing the CMgel and HYPOpcl groups this illumi-
nates the effect of not only compliance but also gelatin concentration. Similarly, the effect of
compliance on differences between the CMgel group and HYPOgen groups is confounded by
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genipin concentration. Future studies will need to address and mitigate these confounding
factors to help further elucidate the role compliance has in TEVG design.
In this study, the approach used to modify compliance was the composition and crosslink-
ing of the TEVG, however there are alternative approaches to accomplish this same goal.
Increasing crosslinking concentration is a common method to decrease graft compliance as
demonstrated in our study and by that of the Abbott et al. group who altered the concen-
trations of glutaraldehyde [33] during crosslinking. Our group has used a similar approach
in the past [45], however have since moved away from this approach due to the cytotoxic
potential of glutaraldehyde in-vivo [21, 84, 85]. Other groups have shifted towards manip-
ulating graft compositional changes to vary compliance [41, 86]. Nezarati el al. created
synthetic polymer grafts with varying thickness, tortuosity, and fiber fusions that were able
to exceed the compliance of the human saphenous vein [41]. Another group modified the
outer PCL sheath thickness which created a TEVG with tunable compliance [86]. While
several researchers have successfully tuned the compliance of TEVGs, none have been able
to match the thickness and compliance of the target vessel simultaneously. In general, most
of the afore mentioned TEVGs and other researchers in the literature are at least several
hundreds of microns thicker than that of rat aorta (approx. 80 µm) which could limit cellular
infiltration, transport, and cellular migration. Soletti et al. showed promise with their graft
thickness, however, their grafts were significantly less compliant than rat aorta [81]. Our
unique method allowed us to create a compliance-matched TEVG that has a similar thick-
ness to rat aorta with a unique and biomimetic multi-layer design which can be modified to
more closely resemble the native vessel. This multi-layer approach could also be tuned to
include naturally occurring biopolymers such as elastin and collagen.
2.5 Conclusion
This study is the first to assess the functional performance of a multi-layered TEVG
that has been compliance-matched using a computational optimization approach. The me-
chanically optimized graft is acutely remodeled to remain compliance-matched in-vivo over
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a 1-month period. The CMgel grafts also demonstrated an increase in collagen produc-
tion within the implant that may emanate from a more desirable macrophage and SMC
response. These results need to be further explored in future studies that thoroughly assess
graft vasoreactivity, graft degradation, and ECM production in graft explants at longer term
explant periods [87]. We believe the results of this study demonstrate the importance of care-
ful control of graft design and how it may influence the in-vivo remodeling and functional
performance of biodegradable TEVGs.
The results of this study support the hypothesis that the compliance of a vascular implant
effect the remodeling of a TEVG and demonstrates its importance. Specifically, compliance
matching a vascular graft increases cellular infiltration and positive cellular remodeling of
the TEVG. In the future, vascular graft designers may use this knowledge as a stepping
stone to help design a better TEVG.
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3.0 Modulating TGFβ2 Elution Alters the Acute Remodeling of a
Compliance-Matched Tissue Engineered Vascular Graft
The goal of this aim was to alter the concentration of TGFβ2 (0 ng/mg, 10 ng/mg, and
100 ng/mg) eluting TEVGs which were either compliance-matched or hypocompliant and
were used to assess cellular infiltration, migration, and proliferation over an acute 5-day pe-
riod. The TEVG was either tuned to be either compliance-matched (CMgel) or hypocompli-
ant (HYPOpcl) to rat aorta using our integrated computation/experimental approach, loaded
with TGFβ2, crosslinked with genipin [28], and then implanted into the aorta of Sprague
Dawley rats for 5 days. Preliminary cellular infiltration was assessed using ultrasound and
the host response was quantified from explant histology.
3.1 Introduction
Designing a functional TEVG requires several key factors including matching the com-
pliance of the graft to the native vasculature (aim 1), the recruitment of smooth muscle cells
(SMC) into the implant, desirable scaffold composition for cellular infiltration, and drug de-
livery for cellular recruitment and phenotypic control. The compliance of the vascular graft
has been shown to have an effect on vascular smooth muscle cell phenotype, inflammatory
response, and overall patency of the TEVG, aim 1 [32, 57, 33]. Moreover, stiff (hypocom-
pliant) grafts change the hemodynamic environment of the vessel that can result in loss of
patency a characteristic often overlooked in TEVG design [42, 43, 44, 34]. SMCs are the ma-
jor muscular component of the vessel responsible for extracellular matrix (ECM) production
and the regulation of vascular tone. Controlling the composition of the TEVG also offers
the unique ability to encourage SMC manipulation through the integration of biomolecules
into the scaffold. One factor of particular interest is transforming growth factor beta 2
(TGFβ2), which has been shown to deferentially modulate SMC phenotype as a function of
concentration in vitro [29]. This growth factor is a pleiotropic cytokine that regulates cell
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cycle, cell differentiation, cell growth, cell death, and ECM deposition/ organization [88, 89].
On a macroscopic scale, TGFβ2 has also been shown to have a role in ECM remodeling
in vascular, cardiac, and embryonic development [90, 91, 92]. Focusing more on vascular
disease, the TGFβ family has been shown to be atheroprotective and atherogenic depending
on concentration [29, 93]. In our laboratory we have shown that SMCs can be recruited by
eluting a low TGFβ2 concentration (0.1 ng/mg) to promote cellular migration, while higher
concentrations can arrest cellular proliferation/migration and promote collagen production
[29]. This low TGFβ2 concentration in vitro has also shown the ability to promote SMC
proliferation/migration on a TEVG scaffold after 5 days of incubation [27]. Thus, incorpo-
rating TGFβ2 into a TEVG could promote earlier SMC proliferation/migration in the graft
in vivo. In this aim, the effects of TGFβ2 concentration on TEVG will be evaluated and
discussed.
3.2 Methods
3.2.1 Optimization Routine for TEVG Formulation
An overview of the study is provided in Figure 10. compliance-matched and hypocom-
pliant TEVGs were formulated using our integrated computational/experimental approach
that predicts alternating layer thickness and gelatin:PCL (G:P) ratio of our graft [52, 28].
Briefly, the material constants were collected for a Fung-type constitutive model based on
biaxial mechanical testing of 20G:80P, 50G:50P, and 80G:20P tubular constructs using our
microbiaxial optomechanical device (MOD) [45, 46, 47, 48, 49, 50, 51]. These properties
were used in a four-node, reduced-integration, axisymmetric finite element model in Abaqus
(Dassault Systemes Simulia, France) in combination with an optimization scheme in Mat-
lab (MathWorks Inc, USA). The model’s open design parameters were G:P ratio and the
thickness of each of the paired layers. The constrained parameters for each construct were
inner diameter, number of paired layers, and total thickness. The output of this approach
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Figure 10: Overview of TGFβ2 study. 1. Compliance-matched and hypocompliant con-
structs were fabricated using a biaxial electrospun method that incorporated TGFβ2 con-
centrations at 0, 10, 100 ng/mg. 2. Constructs were crosslinked in 0.5% w/v genipin for 24
hrs at 37◦C. 3. The TEVGs (n=3 for each group) were implanted in the abdominal aorta of
a Sprague Dawley rat for 5 days. 4. Before surgery and 5 days after implantation the TEVG
was imaged using ultrasound. 5. Histological markers were used to evaluate host response.
matched and hypocompliant to rat aortic values with approximately sixty-five and thirty
percent gelatin, respectively. The TEVG formulations are found in Table 2.
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3.2.2 Graft Material and Fabrication
The constructs were fabricated using an biaxail syringe setup with IME electrospinning
device that included a climate-controlled chamber and gas shield to prevent buildup (Waalre,
Netherlands). For this process, gelatin extracted from porcine skin (Sigma-Aldrich) and PCL
with a molecular weight 80,000 (Sigma-Aldrich, St. Louis, MO) were dissolved in 1,1,1,3,3,3-
hexafluoro-2-propanol (HFP) (Sigma-Aldrich) to create a 10% w/v solution. The polymeric
formulations for biaxial electrospinning were 75:25 & 50:50 G:P and 20:80 & 35:65 G:P
for the compliance-matched (CMgel) and hypocompliant constructs (HYPOpcl), respectively.
The polymeric solutions were loaded into 5ml BD syringes (BD Franklin Lakes, NJ) and
lyophilized recombinant human TGFβ2 (R&D systems) was reconstituted with 4mM HCL
containing 1mg/ml bovine serum albumin (BSA) (SigmaAldrich, USA). TGFβ2 was added
to each syringe based on the ratio of total gelatin percentage of the two formulations. For
example, one construct layer had a syringe filled with a 75% and the other a 50% gelatin
concentration, thus this ratio of 3:2 was used as the amount of TGFβ2 mass to assign to
each syringe. The polymer blends and TGFβ2 were mixed to create a final TGFβ2 mass of
0, 10, or 100 ng per mg of scaffold [29].
Once mixed for 24 hours, the electrospinning solutions were both loaded onto separate
computer-controlled syringe pumps and connected to IME electrospinning device through
1 mm PTFE tubing. The electrospinning parameters were as follows: working distance of
10 cm, dispense rate of 50 µL/min (both syringes), and 15-kV voltage. Constructs were
spun onto a 1.1 mm diameter steel rod rotating at 300 mm/s with a tip translation of 300
m/s. The climate and humidity were set to 25◦C and 30%, respectively. Before creating the
construct, each syringe pump was primed and checked for solution extrusion. The higher
gelatin formulation was spun from the vertical nozzle to help prevent buildup on the tip. Each
layer was extruded sequentially which took about 4 minutes per layer to allow dissipation of
the line pressure. Following the completion of the electronspinning process, the constructs
were soaked and shaken in 0.5% (w/v) genipin (Wako Chemicals USA Inc, USA) in 200 proof
ethanol for 24 hrs at 37◦C to crosslink gelatin [28]. Following crosslinking, the constructs
were then rinsed with 200 proof ethanol and implanted within 24 hours.
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3.2.3 Rat Aortic Implantation
The TEVGs were implanted into the abdominal aorta of 8-week-old Sprague Dawley
rats for 5 days. The compliance-matched and hypocompliant TEVG contained 0, 10, or
100 ng/mg TGFβ2 concentration with n=3 in each group for a total of 18 animals (males
and females distributed within each group). The interpositional abdominal aortic surgical
procedure followed closely the protocol described by Niepionce [80] and recently used by our
group [32]. To begin the surgery, each rat was anesthetized with isoflurane (3% for induction
and 1% for maintenance) for the duration of the study. Next, the fur was removed by using
NairTM with a paper towel and a 3-4 cm incision with a No. 10 scalpel was made on the
medial abdominal wall. The small intestines and cecum were removed from the abdominal
cavity and covered with heparin soaked gauze to prevent dehydration and clotting. The aorta
was isolated (1 cm above the bifurcation) from connective tissue, side branches were ligated
and transected, and two 30 g clips were applied to the bifurcation and ilolumbar artery to
arrest blood flow. The aorta was transected, the lumen of the vessel was irrigated by saline,
and the anastomosis was initiated at the proximal region of the vessel with stay sutures
using a 10-0 nylon placed at the 3 and 9 o’clock positions. Three or four stitches were added
to the anterior wall and then the vessel was rotated 180o clockwise with a similar amount
of stitches added to the posterior wall. A similar procedure was performed on the distal
anastomosis. Before the last suture was placed, the lumen of the implant was irrigated with
saline. The clips were then removed and the vessel was assessed for patency using a perfusion
test. If bleeding occurred, pressure was applied to the suture line until bleeding stopped. On
occasion, an extra suture would be placed on a distal suture if bleeding persisted. In general,
each anastomosis had around 7-10 stitches per end. After completion of the anastomosis,
the small intestines and cecum were returned to the abdominal cavity, the rectus abdominis
was closed using an interrupted 4-0 absorbable polyfilament suture, and skin was stapled
closed.
Upon completion of the surgery, each rat received two daily intramuscular injections of
0.5mg/kg buprenorphine and 100mg/kg cefuroxime for the first three days to minimize pain
and prevent bacterial infections, respectively. All solid medication was pulverized, mixed
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Layer Thickness (µm) Genipin
(w/v)
Sample Size
L1 L2 Repeats Total 0 10 100
CM 75:25 50:50 8 5 6 78 0.5 3 3 3
Hypo 20:80 35:65 8 5 6 78 0.5 3 3 3
with jelly, put into a small ice cream cone, and fed to the rat. Inflammation was minimized
by feeding the rat carprofen (5mg/kg) at 24 and 48 hrs post operatively. Aspirin (pain
reliever) and dipyridamole (antiplatelet agent) were also fed to the rat at a concentration of
200 mg/kg and 250 mg/kg for duration of the study. After 5 days, the graft was recovered
by euthanizing the rat and fixed in a 4% paraformaldehyde solution in PBS (Thermo Fisher
Scientific, Waltham, MA).
3.2.4 Measurements and Quantification of Outcomes
3.2.4.1 In Vivo Ultrasound
Graft patency, diameter, compliance, and maximum blood velocity were collected us-
ing high frequency ultrasound (VEVO 2100 FUJIFILM VisualSonics Inc, Canada) with a
MS400 30 MHz probe. The rats were imaged for up to one week before surgery and 5
days post implantation. Ultrasound data was collected by anesthetizing the rat with isoflu-
rane (3% for induction and 1% for maintenance), removing the fur with Nair Hair Removal
(Church & Dwight), and imaging the abdominal aorta cross-sectionally and longitudinally.
In general, cross sectional imaging was used for identifying the aorta and patency, while
diameter/compliance measurements and velocity were calculated longitudinally. Patency
was determined by using ultrasound to observe flow through the entirety of the implant.
All ultrasound measurements and calculations were determined using the Vevo Lab software
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version 1.7.1. In vivo rat compliance was calculated from the inner minimum and maximum





The 50 mmhg in the denominator of the compliance equation was constant for all animals
and represented the difference in theoretical pressure. The inner minimum and maximum
diameters were then averaged to determine the diameter of the vessel. Using Doppler ultra-
sound, the maximum velocity of 3 waveforms per rat was used and adjusted for probe angle
[55]. All ultrasound data was checked for normality using a Shapiro–Wilk test and compared
to healthy rat aorta using a one-way ANOVA with Tukey post hoc testing. The length of
the construct was assessed using a one-way ANOVA with a Tukey post hoc analysis.
3.2.4.2 Immunohistochemistry and Fluorescent Imaging
All TEVGs were evaluated for cellular markers and construct remodeling. Each ex-
plant was cut in half, separated into proximal and distal portions, frozen in O.C.T. medium,
and cut into 10 µm thick sections using a Microm HM550 cryostat microtome. The proximal
portion of the sample was cut longitudinally and the distal part was cut cross-sectionally at
the mid-graft location.
For immunohistochemistry, samples were rehydrated in PBS and then soaked in 1%
sodium dodecyl sulfate (Sigma-Aldrich, St. Louis, MO) in PBS for 15 minutes. The samples
were next permeabilized in 0.3% triton X-100 (Sigma-Aldrich) for 15 minutes and blocked
with 0.5% bovine serum albumin (Sigma-Aldrich), 0.3 M glycine (Thermo Fisher Scientific),
and 20% goat serum (Thermo Fisher Scientific) for one hour. Following blocking, all samples
were incubated with primary antibodies over night at 4◦C. α-Smooth muscle actin (αSMA),
calponin (CAL), and smooth muscle myosin heavy chain (MHC) were used to detect smooth
muscle cells. Highly proliferative cells were labeled with Ki67 and the samples were also
labeled for elastin. The inflammatory response was determined using CD68, CD86 and
CD163 for pan, M1, and M2 macrophage phenotypes, respectively. All primary antibodies
were used at a ratio of 1:100 and purchased from Abcam. After incubation and washing,
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the samples were incubated for 1 hour at room temperature with Alexa Fluor 488 Goat
Anti-Rabbit IgG (Abcam, 1:1000) except for αSMA which was incubated with Alexa Fluor
488 Donkey anti-goat IgG (Abcam, 1:1000). Each sample was washed and counterstained
with DAPI mounting medium (Abcam).
Cellular markers were evaluated using using a Nikon 90i Eclipse fluorescence microscope.
Each section was imaged entirely using DAPI (excitation at 359 nm; emission at 461), FITC
(excitation at 495 nm; emission at 519 nm), and Cy5 (excitation at 647; emission at 665)
emission channels using a Nikon Plan Apo 10x/0.45 objective. Cell nuclei, implant, and
marker were identified in DAPI, Cy5 (autofluorescence from genipin), and FITC channel,
respectively. The exposure time for the FITC channel was consistent between all samples of
the same marker to quantitatively assess difference between samples.
3.2.4.3 Multiphoton Imaging
Collagen was imaged using second harmonic generation using the Pitt Advanced Intrav-
ital Microscope at the University of Pittsburgh for the cross-sectionally and longitudinally
sectioned samples. For this setup, an Olympus BX51 upright scanning microscope (Olym-
pus, Tokyo, Japan) was coupled into a 120-fs tunable pulsed laser (INSIGHT DS+DUAL,
Newport, Irving CA) and Olympus XLUMPLFL 20x water emersion objective (NA 0.9).
Collagen fibers were imaged at 780 nm and collected with a bandpass filter 377/50 nm with
a power 118-152 mW using second harmonic generation. DAPI and autofluorescence was
also imaged at 780 nm with a power of 25-31 mW and collected with 525/50 nm and 620/60
nm bandpass filter, respectively. The signal was collected over multiple 499 x 499 µm fields
of view with a 5 µm z-step-size through the entire thickness of the sample. Mosaic images
of each channel (377, 525, and 620 nm) were converted into maximum intensity projections
and used for image processing.
For processing, the images were used to calculate abluminal number of cells, construct
thickness, and total collagen. The construct thickness was measured for each explant and
compared using a one-way ANOVA. The cells inside the construct and in the abluminal
region were calculated using the ImageJ (Fiji) particle function. Percent collagen in the
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samples was calculated the same as the antibody image processing discussed in the section
below (Section 3.2.4.4).
3.2.4.4 Image Processing
Fluorescent signal was collected using a Nikon 90i Eclipse fluorescence microscope in three
channels DAPI, FITC, and Cy5 which were faux colored with blue for cell nuclei channel,
green for implant channel (green), and red for the antibody or collagen channel, respectively.
All images were processed using Matlab to determine antibody signal differences between
each group. FITC signal was binarized to remove background noise and identify the pixels
of interest (POI). The amount of signal per sample was calculated by dividing the pixels of
interest by the total number of pixels (POI/TP) in a certain area. For collagen specifically,
the sample had a high amount of noise which also required the collagen image to be despeck-
led. All marker calculations were done for the proximal and middle sections. The markers
for each group 0, 10, 100 ng/mg were checked for normality and compared using a one-way
ANOVA with Tukey posthoc testing.
3.3 Results
3.3.1 Construct Characterization
Previous work quantified the compliance-matched and hypocompliant TEVG burst pres-
sure, suture retention, and compliance which were 504±164 & 1435±107 mmHg , 11±2 &
43.5±15 g, and matched compliance & twice as stiff as rat aorta, respectively [32]. The
overall release profile of TGFβ2 from the compliance-matched and hypocompliant construct
were evaluated in Ardila et al. with around 1 - 1.5 and 0.05 % of the total growth factor
released from each construct by 5 days [27].
For the surgery, no complications or adverse events occurred with all animals surviving
the duration of the study. Each surgery generally lasted around one and a half hours with
the anastomosis time taking approximately 50 minutes. The average implant length for
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the compliance-matched constructs were 0, 10, and 100 ng/mg were 7.7±0.7, 6.9±0.2, and
6.6±0.8 mm, respectively, with no difference between groups. The hypocompliant TEVGs
average length for 0, 10, and 100 ng/mg were 6±0.5, 5.7±0.6, and 6.4±0.3 mm, respectively,
with no difference between groups. The 100 ng/mg compliance-matched construct thickness
was found to be thinner than the 10 ng/mg construct (59±6 vs. 74±4 µm, p = 0.04) with
no difference in relation to the 0 ng/mg construct (71±4 µm), Figure 12. The thickness of
hypocompliant constructs were all similar.
3.3.2 Ultrasound
Ultrasound imaging confirmed patency in all groups throughout the duration of the
study. The compliance-matched constructs were found to decrease in compliance as the
concentration of TGFβ2 increased. Specifically, the 100 ng/mg group was considerably
stiffer than the native rat aorta, 17±2x10−4 (0 ng/mg) to 11±1x10−4 mmHg−1 (100 ng/mg).
The diameter and maximum velocity for all compliance-matched groups did not differ from
native rat aorta tissue. In general, the average implant diameter and velocity was around
1000 µm and 700 mm/s, respectively. These results can be found in Figure 11.
The compliance of the hypocompliant grafts for 0, 10, 100 ng/mg were 8.7±3x10−4,
6.3±1x10−4, 8±2x10−4 mmHg−1 with each graft being significantly stiffer than native rat
aorta, p<0.0001 for all comparisons. The diameter and velocity of the hypocompliant TEVGs
were similar to that of native rat aorta (Figure 11).
3.3.3 Multiphoton Imaging
Multiphoton images representing the hypocompliant (blue) and compliance (orange)
TEVGs for the 0, 10, 100 TGFβ2 ng/mg 5 day explant groups are shown in Figure 12
with green being the construct and blue cell nuclei. The overall cell count (lumen, implant,
and abluminal) for the compliance-matched implant was generally similar between the 0 and
100 ng/mg groups with the least amount of cells in the 10 ng/mg group. Cellular infiltration
decreased in the compliance-matched TEVG with increasing concentrations of TGFβ2, 0 vs.
100 ng/mg (3600±1700 vs. 770±300 cells, p<0.05). TGFβ2 had the opposite effect on the
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Figure 11: Compliance, diameter, and maximum velocity of 0, 10, 100 ng/mg of constructs.
Orange and blue bars indicate compliance-matched and hypocompliant TEVG implants, re-
spectively. The red dashed lines represent rat aorta. The compliance matched constructs
became less compliant as the concentration of TGFβ2 increase, while the hypocompliant
construct remained stiff over all concentration. The diameter and maximum velocity re-
mained similar to rat aorta for all groups. ∗∗ = p<0.01 and # = p<0.0001 in reference to
rat aorta
abluminal cell count in compliance-matched TEVGs with the 100 ng/mg construct having
the most cells compared to the 10 ng/mg construct (6820±1670 vs. 200±140 cells, p<0.05).
For the hypocompliant TEVGs, cellular infiltration into the construct and abluminal region
were found to be similar between all constructs.
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Figure 12: Compliance, diameter, and maximum velocity of 0, 10, 100 ng/mg of constructs.
Orange and blue bar graphs indicate compliance-matched and hypocompliant TEVG im-
plants, respectively. All hypocompliant grafts had a similar implant thickness and cells
inside & outside the TEVGs. The increase of TGFβ2 in the CM constructs reduced the
amount of cells in the construct, but increased the abluminal cells in the 100 ng/mg group.
Scale bar is 100 µm. The compliant-match 100 ng/mg group was also found to be slightly
thinner than the 10 ng/mg group. n=3 for each group; ∗ = p<0.05 and ∗∗ = p<0.01
compared to rat aorta.
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3.3.4 Immunohistochemistry
Sample longitudinal and cross sectional slices were stained for SMCs, macrophages, and
ECM products with the results shown in Figure 13 and Figure 14. The 5 day proximal
portion of the compliance-matched explant showed that the 100 ng/mg group had a reduction
in SMCs but an increase in CD68 (M1 macrophage) and collagen. There was also a dramatic
increase in MHC of the 10 ng/mg compared to 0 and 100 ng/mg in the compliance-matched
grafts. On the other hand, the hypocompliant constructs showed no differences in the prox-
imal and middle location of the grafts for all markers and ECM products, Supplemental
Figure 1 and Supplemental Figure 2.
For the proximal location of the compliance-matched grafts (Figure 13), the SMCs
population was measured using αSMA, calponin, and MHC with differences only occurring
in the MHC marker. Specifically, there was a decrease in MHC signal in the 100 ng/mg
group compared to the 0 and 10 ng/mg (0.0019±0.002 vs. 0.024±0.003 & 0.029±0.013
POI/TP, p<0.05). The Ki67 label did not show any differences between the groups. The
definitive markers CD86 and CD163 displayed no differences between groups, but the gen-
eral macrophage marker CD68 was increased in the 100 versus 10 ng/mg (0.055±0.23 vs.
0.015±0.001 POI/T, p<0.04). ECM production of collagen increased with increasing con-
centrations of TGFβ2, 0, 10, and 100 ng/mg (0.002±0.002 to 0.003±0.001 to 0.008±0.002
POI/TP, p<0.05 0 to 100). Overall elastin amounts in the ECM were found to be similar
between all groups.
For the middle location of the compliance-matched grafts, MHC again was the only SMC
marker to show differences between groups with a drastic increase in signal for 10 ng/mg
group compared to the 0 and 100 ng/mg groups (0.03±0.006 vs. 0.005±0.002 & 0.003±0.005
POI/TP). No other differences were found in the macrophage, Ki67, and ECM markers which
are further highlighted in Figure 14.
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Figure 13: Compliance-matched proximal immunofluorescence images and immunohisto-
chemistry results. The TEVG, nuclei, and each marker are green, blue, and red respectively.
Immunohistochemistry quantification of the signal from MHC, pan macrophages (CD68),
collagen, αSMC, calponin, Ki67, M1 (CD86), M2 (CD163), and elastin. Increasing the con-
centration of TGFβ2 decreased MHC signal and increased CD68 & collagen deposition in
the 100 ng/mg group. ∗ = p<0.05; ∗∗ = p<0.01; X axis = TGFβ2 concentration (ng/mg);
Y axis = Pixels of Interest/Total Pixels; Scale bar is 50 µm
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Figure 14: Compliance-matched midgraft immunofluorescence images and IHC results. Con-
struct is green, cell nuclei is blue, and maker is red. Immunohistochemistry quantification
of the signal form αSMC, MHC, M2 (CD163), calponin, Ki67, pan macrophage (CD68),
M1 (CD86), elastin, and collagen. The 10 ng/mg compliance-matched construct had signif-
icantly more MHC signal than the 0 and 100 ng/mg groups. No differences were found in
any other markers. ∗ = p<0.05; ∗∗∗ = p<0.001; Y axis = Pixels of Interest/Total Pixels;
X axis = TGFβ2 concentration (ng/mg); Scale bar is 50 µm
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3.4 Discussion
The incorporation of TGFβ2 in compliance-matched TEVGs (faster degrading scaffold)
increased SMC infiltration and collagen production over an acute 5-day period. Specifically,
low TGFβ2 concentrations (10 ng/mg) caused an increase in the MHC SMC marker at
both the proximal and middle locations of the graft. The high concentration of TGFβ2
(100 ng/mg) in the compliance-matched grafts increased collagen production in the proximal
region, halted SMC infiltration, and caused the TEVG to stiffen. The hypocompliant TEVGs
(slower degrading scaffolds) displayed cellular infiltration and ECM production and were
unaffected by any TGFβ2 concentrations. These results demonstrate that the elution of
TGFβ2 from a TEVG can promote in vivo SMC recruitment and collagen production even
after only an acute 5-day implantation period.
SMCs are vital to TEVG remodeling as they are one of the key cell types for vessel
functionality. For example, the contractile phenotype is usually found in a mature vessel
where it regulates vascular tone, ECM production, and minimizes cellular migration [94]. In
contrast, synthetic SMCs are generally found in more immature vessels which have a higher
rate of proliferation and migrate much faster across a substrate [95]. TGFβ2 and the TGFβ
family are key signaling molecules that regulate SMC phenotype depending on concentration
[29, 96, 97, 98, 99]. At low concentrations, the TGFβ family has been found to increase SMC
proliferation through the promotion of platelet derived growth factor (PDGF) which in turn
stimulates DNA synthesis [98, 100]. At higher TGFβ concentrations, PDGF expression
is limited which arrests SMC proliferation and leads to an increase in ECM production
[98]. These results have been confirmed in SMCs exposed to high levels of TGFβ1 that
induced collagen synthesis (Kubota el al [101]). In the context of this work and TGFβ2,
Ardila et al. demonstrated in vitro that using low (<0.01 ng/ml) and high (>5 ng/ml)
exogenous TGFβ2 concentrations in electrospun gelatin:fibrinogen scaffolds promoted SMC
proliferation and collagen production, respectively [29]. Our laboratory has taken the next
step and implanted TGFβ2-eluting, compliance-matched constructs into a rat model for 5
days showing similar results with increased SMCs (MHC marker) at low concentrations and
higher collagen content at 100 ng/mg. Using this knowledge, the elution of TGFβ2 from the
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TEVG could be modified to promote SMC infiltration and collagen deposition subsequently.
For example, Jhunjhunwala et al. demonstrated that TGFβ1 could be released at low
levels for 3 weeks followed by an increased release until around 50 days using microparticle
encapsulation [102]. This microparticle release profile could also be transferred to TGFβ2
and is currently being evaluated in our laboratory.
A substantial portion of TEVG research is focused on SMCs, however the immune re-
sponse to the implant plays an equally important role in the success of the TEVG. Immune
responses to the TEVG are broken down into the inflammatory and wound healing response
[103, 104]. The inflammatory response which is closely tied to M1 macrophages (CD86)
promotes encapsulation of the tissue, destruction of foreign bodies, and impeded growth
[104]. While it is necessary to have this inflammatory response early on to increase the
cellular population around the implant and protect the body against foreign material, a
prolonged or exaggerated immune reaction can be detrimental to the TEVG [105]. Thus,
promoting these M1 macrophages to move towards the M2 phenotype (CD163) encourages
cellular growth around the implant, ECM production, and neovessel formation [106]. In this
study, the results demonstrate the initial response to the implant with only noticeable dif-
ferences in macrophages shown in the CD68 marker (generalized macrophage marker) of the
100 ng/mg compliance-matched group in the proximal location. These results suggest that
increasing TGFβ2 promotes an exaggerated immune response, which has also been shown
to occur in other TGFβ-influenced environments [107]. Prior work in our laboratory has
also evaluated immune cells at a longer time point. Specifically, the 0 ng/mg compliance-
matched implant has been previously implanted in Sprague Dawley rats for one month and
compared to a hypocompliant control TEVG. The M2/M1 ratio of macrophages in the 0
ng/mg compliance-matched grafts were found to be higher than in the hypocompliant grafts
[32]. Thus, suggesting that the compliance of the implant is more suitable for positive TEVG
remodeling. While there are no noticeable differences in M1 and M2 population at 5 days
in the compliance-matched construct, we anticipate this M2/M1 ratio may carry over in the
10 and 100 ng/mg groups in future studies. Longer time points and larger sample size will
need to occur before there is a clear understanding of the longer term effects of TGFβ2 on
TEVG remodeling.
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One major difference between the compliance-matched and the hypocompliant grafts
were the degradation rate of the scaffold [27]. Previous work has shown that the compliance-
matched construct degrades twice as much as the hypocompliant graft in one month [32].
This degradation of the scaffold is vital for the release of TGFβ2. Past in vitro work
has shown that in 5 days the compliance-matched TEVG can elute about 20 to 30 times
more TGFβ2 than the hypocompliant grafts [27]. Thus, the reduced degradation/elution
of hypocompliant constructs is believed to be the reason why there were no differences be-
tween any of the hypocompliant groups in this work. This is surprising considering that
the 100 ng/mg hypocompliant group has an order of magnitude more TGFβ2 than the 10
ng/mg. Another reason for the lack of TGFβ2 release from both scaffolds may emanate
from the genipin crosslinking procedure. Each construct is submerged in 0.5% genipin in
100% ethanol at 37o and shaken for 24 hrs. During this procedure, any loose or unbound
TGFβ2 may be eluted into the genipin solution which would reduce the amount of growth
factor available. A potential solution to prevent the loss of TGFβ2 is to explore alternative
crosslinking procedures such as using ultraviolet light, vapor, chemical, or plasma treatment
[108]. Future testing could incorporate one of these crosslinking methods to prevent the
potential loss of TGFβ2 during the fabrication process.
One unexpected result from this work was the decreased compliance in the 100 ng/mg
compliance-matched construct compared to rat aorta. Specifically, this graft stiffening comes
as even more of a surprise due to the acute nature of the implantation period and the decrease
in implant thickness of the 100 ng/mg compliance-matched construct ( 60 µm) in reference
to the 0 and 100 ng/mg groups. This decrease of compliance is related to the increase of
cells in the abluminal region of the 100 ng/mg group. All 100 ng/mg compliance-matched
samples had large abluminal populations compared to the vastly varying abluminal cellular
populations of the 0 and 10 ng/mg TEVGs. To further understand these results, our labo-
ratory has also investigated the 100 ng/mg compliance-matched and hypocompliant grafts
at a 4 week implant (Supplemental Figure 3) and found that this decrease of compliance
also led to an increase in luminal thickness and cellular alignment compared to 0 ng/mg at
4 weeks. As these results and previous literature suggest, TGFβ can be atheroprotective
and atherogenic depending on the cellular environment [29, 93]. The increase in alignment
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demonstrates that high TGFβ2 concentrations may promote a contractile SMC phenotype,
but could also encourage intimal hyperplasia. This increase of intimal hyperplasia could be
related to the endothelial-to-mesenchymal transition of endothelial cells in the TEVG. From
previous work, high TGFβ concentrations in mouse endothelial cells cause cells to become
more leaky, transition to an mesenchymal state, and lead to increased atherosclerotic lesion
markers [109, 110]. Controlling the concentration and release of TGFβ2 from compliance-
matched TEVGs will be ideal for maintenance of compliance as the graft is remodeled in
vivo.
All TEVGs remained patent throughout the time course of this work. These initial
results suggest that the inclusion of TGFβ2 does not affect in vivo patency, velocity, or
diameter over a 5-day period. This is consistent with our prior work showing that the
velocity, diameter, and compliance of 0 ng/mg implanted TEVGs remained similar over a
four-week implantation period [32]. The only drawback from our previous study was that
both compliance-matched and hypocompliant grafts clotted in 2/7 and 1/7 of the trials,
respectively (no significant differences between groups).
A major limitation of this study was the short 5-day implantation period. The motivation
for this work and selection of study duration, as stated previously, was to relate to prior
work done by Ardila et al [27]. Her in vitro study and this work confirm that low TGFβ2
concentrations promote SMC proliferation and migration in a TEVG over an acute period.
Another limitation in the current study was the small sample size, n=3, which was mainly
selected to demonstrate the potential of TGFβ2-eluting TEVGs. Further TGFβ2 studies
are needed to fine tune in vivo TGFβ2 release such as concentration, elution profile, and
timing. Our current working hypothesis of TGFβ2 release is that a low concentration will
promote early SMC infiltration and a subsequent higher dose will promote ECM production
that will stabilize the compliance of our fully biodegradable TEVG. While these results are
promising, other factors will have to be taken into account to find the ideal TGFβ2 release
profile for a particular animal species, side effects of TGFβ2, graft composition (as shown
in our hypocompliant group), and several other factors. The acute response of the host
to TGFβ2 in this study will hopefully spawn additional future research exploring the next
generation of TEVGs that elute bioactive factors to improve functional in vivo performance.
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While TGFβ and its family of cytokines has been given significant attention in the
literature, studies that focus on the exogenous delivery of the TGFβ2 isoform specifically
are limited. This is important to note as there may be fundamental differences in the
binding between TGFβ 1 & 2 and the actions of TGFβ1 may not always relate directly to
TGFβ2 [111, 112]. For example, the RGD (Arg-Gly-Asp) integrin binding region found in
the LAP of TGFβ1 and TGFβ3 is lacking in TGFβ2 which suggests that it may have a
different method of activation [113]. This may play a role in functional differences during
cardiovascular development, as heterozygous TGFβ1 knockout mice function similarly to
wild type animals, whereas TGFβ2 mice present with aortic root dissection [114]. In terms
of vascular remodeling, TGFβ is again a regulator of cellular migration/proliferation at low
concentrations and prevents movement at higher concentrations [93]. This growth factor not
only affects SMCs but endothelial cells, macrophages, and lymphocytes. The exact timing
and concentration of TGFβ elution are key for success or failure in vivo. For example, high
TGFβ concentrations early may prevent endothelial cell migration into the implant [115],
thus increasing the likelihood of a possible thrombotic event. In contrast, a higher TGFβ
concentration later may promote collagen development in the TEVGs. Elevated TGFβ levels
may not be ideal after the initial implantation once the vessel has matured. Specifically, the
upregulation of TGFβ can promote an increase in collagen production to stiffen the vessel
and lead to calcification [93]. These results have been demonstrated in a rat and a rabbit
model with the addition of exogenous TGFβ or after a vascular injury [116, 117]. Thrombotic
events may occur more frequently as well as TGFβ1 is less at efficient at clearing thrombosis
formation due to an increase in plasminogen activator inhibitor activity [118]. Keeping all
of these factors in mind, the delivery of TGFβ will need to be tightly controlled for a desired
long term functional outcome.
3.5 Conclusion
To the author’s knowledge, this is the first study to assess in vivo TGFβ2 release
from a compliance-matched and hypocompliant TEVG over an acute 5-day period. His-
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torically, TGFβ2 has been found to be a potent SMC phenotype modulator and this was
confirmed through the in vivo work in this study. As TGFβ2 concentrations increased in the
compliance-matched constructs the production of collagen was elevated, the SMC popula-
tion was reduced, the TEVG became less compliant, and caused a larger immune response.
On the other hand, the lower concentration of TGFβ2 in the compliance-matched construct
increased SMC infiltration and proliferation. The degradation of the scaffold was key to
TGFβ2 elution as the slower degrading hypocompliant construct had no affect on the cellu-
lar environment or implant. We believe this work demonstrated that TGFβ2 incorporated
into a TEVG was beneficial for SMC migration, proliferation, collagen production, and hope
this study will inspire new studies in the vascular tissue engineering field.
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4.0 Tracking Delivery of a Drug Surrogate in the Porcine Coronary Artery
Using Photoacoustic Imaging and Spectroscopy
This aim will focus on an alternative imaging technique to evaluate in vivo drug delivery
and degradation from a TEVG or a stent. This technique, photoacoustic imaging, uses a
combination of ultrasound and a tunable laser light source to identify known absorbers or
dyes in the surrounding medium. The porcine heart, vasculature, and coronary arteries will
be exposed to a dye and a method will be developed to determine dye concentration and
location. This method could pave the way for future in vivo imaging for the evaluation of
drug release from a TEVG (aim 2) or degradation in vascular grafts.
4.1 Introduction
Throughout this dissertation, the primary focus has been on evaluating compliance spe-
cific and eluting TEVGs through ultrasonic, histological/fluorescence, and multiphoton imag-
ing. Here we look to expand our standard method of TEVG evaluation with the incorpora-
tion of photoacoustic imaging and spectroscopy (PAIS). This technique combines ultrasonic
imaging with a non-ionizing tunable laser to provide sub-mm in vivo resolution, millimeters
of depth penetration, and the ability to detect wavelength specific absorbers in the tissue.
Specifically, this technique is based on the photoacoustic effect, which starts from the tissue
absorbing a short pulse of light that causes transient heating leading to thermoelastic expan-
sion that generates a sound wave which is detected by an utlrasonic probe. The sound waves
are used to create an ultrasonic image with contrast that is proportional to the absorption of
light. The distribution and relative concentration of optically absorbing contrast agents in
the implant can also be estimated through the scanning of multiple wavelength and spectral
decomposition.
PAIS offers many advantages over other imaging modalities. For example, while mag-
netic resonance imaging [MRI], computed tomography [CT], and ultrasound [US], are ca-
pable of anatomical and functional imaging of the heart and implant, they typically lack
57
sufficient contrast to identify and track pharmacological compounds in the vasculature and
myocardium. Standard techniques to evaluate vascular grafts such as ultrasonic, histological
or fluorescence, and multiphoton imaging have some major drawbacks as well. For exam-
ple, fluorescence microscopy and histology are used to identify specific cells or components
but require explantation and destruction of the tissue. Lastly, multiphoton confocal mi-
croscopy has the ability to provide in vivo imaging but is limited in depth penetration, <1
mm [119, 120, 121]. PAIS provides high contrast and specificity for detecting and tracking
optically-absorbing compounds in the vascular tissue, implant, and myocardium. These at-
tributes are not only favorable for testing and improving the performance of a vascular graft,
but the technology is potentially translatable for in vivo imaging in small/large animals and
humans.
Another major aspect of this aim is to evaluate another style of vascular graft, stent. As
mentioned before, this device is a tubular structure often made of metal that can be deformed
to prop open a narrowed or atherosclerotic vessel. Specifically, stent implantation or percu-
taneous coronary intervention (PCI) is performed in almost 0.5 million cases each year in the
U.S. [122]. This procedure often acts as an noninvasive alternative to TEVG implantation as
most procedures are performed by insertion of a catheter through the femoral artery. Since
the inception of PCI, this procedure has led to major advancements in stent technology, drug
eluting stents (DES), through the incorporation of drugs onto the stent. DES restenosis has
also been reduced over the years by improving drug retention and transport in the coronary
arteries through modification of the drug’s chemical structure [123, 124]. These drugs work
by targeting the smooth muscle cells in the tunica media to reduce or prevent the migration
and proliferation leading to atherosclerosis [125]. Yet there is still concern about failure rates
from vessel restenosis with cases occurring in up to 20% of patients [122, 126, 127, 128, 129].
One of the underlying themes in this work was to also monitor or visualize drug delivery
to the coronary artery using PAIS. From past work, we have shown that drug transport
and mechanical properties of the porcine coronary arteries vary as a function of vessel and
location [119, 130, 131]. However, currently, there is no ideal imaging modality to monitor
and quantify drug delivery to the coronary artery with sub-mm precision.
In this study, we chose to test the feasibility of using PAIS in an explanted porcine
58
heart and vasculature. The primary focus of this work was to evaluate transport from a
drug surrogate. This method uses an ex vivo model which eliminates the need to keep
the tissue alive and focuses on refining the PAIS technique through the calibration and
quantification of the photoacoustic signal. In the final aspect of this work, we fabricated a
stent, coated with a drug surrogate (also a PA contrast agent), and track its position in the
intact porcine brachiocephalic trunk, demonstrating this technique could be used in a large
animal carotid model. Overall, we hypothesize that noninvasive imaging of vascular grafts
will provide real time feed back about the graft and be able to monitor in vivo drug delivery
[119, 123, 130, 131, 132, 133, 134, 135, 136].
4.2 Methods
4.2.1 PAIS Setup and Dye
Optical and Ultrasound Setup (Figure 15A): A wavelength-tunable laser (Surelite-II
OPO, Continuum, 5 nsec pulses, 20 Hz pulse repetition rate, 20 mJ/pulse) operating between
410nm–670nm was coupled into a 1.6 mm diameter multimode optical fiber (CeramOptec)
that connected to a “photoacoustic enabling device” (PED). Specifically, the PED held both
the optical components and linear ultrasound array (Zonare L10-5, 7.1 MHz center frequency,
5 MHz bandwidth) for co-registered pulse echo and photoacoustic imaging, which has been
previously described [137, 138]. Furthermore, the PED allowed for co-alignment between
the optical illumination and plane of ultrasound detection. Briefly, light from the fiber
passed through a cylindrical lens to provide line illumination at the surface of the tissue.
The backscattered photoacoustic waves were reflected by an inline acoustic reflector before
being detected by the linear array and recorded in real-time by a clinical ultrasound scanner
(zOneUltra, Zonare Medical Systems). The PED was filled with water for acoustic coupling.
Raw frame data (amplitude and phase) were transferred from the scanner to a personal
computer running MATLABTM for sum-delay beamforming and post signal processing. The
axial and lateral resolutions of the photoacoustic imaging system were 300 µm and 400 µm,
respectively [137]. The slice thickness was approximately 2 mm. The fluence on the surface of
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the heart was 10 mJ/cm2 and below the American National Standards Institute safety limit
of 20 mJ/cm2 per pulse light at visible wavelengths following American National Standards
Institute Z136.1.
Figure 15: Photoacoustic Imaging setup and Optical Properties of DiI. A) Nd: YAG
laser was tripled to 355 nm to pump an optical parametric oscillator (OPO) and produce
tunable 5 nsec pulses between 410 nm – 670 nm. Laser light was coupled into a 1.6 mm
diameter multimode glass fiber. The fiber connected to a PA flashlight adapter, including
an optical assembly with a cylindrical lens to produce a line pattern on the heart [20]. The
adapter also contained a water-filled cavity for acoustic coupling and an acoustic reflector,
which ensures co-alignment of the light with the plane of ultrasound detection. A clinical
ultrasound scanner (ZoneUltra, Zonare Medical Systems) and 7 MHz linear array (L10-5)
recorded the raw acoustic signals (phase and amplitude) for ultrasound and PA imaging.
The frame data were transferred to a PC for beamforming, post processing and analysis in
MATLABTM. B) Optical absorption spectrum of DiI as measured with a photospectrometer
(Ocean Optics, USB4000).
Drug Surrogate: 1,1’-Dioctadecyl-3,3,3’,3’-Tertramethyllindocarbocyanine Perchlorate
(DiI) was selected for PA imaging due to its weight match to rapamycin, hydrophobic nature,
cost, and favorable absorbance spectrum at visible wavelengths (Figure 15B) [119]. DiI
was acquired from Invitrogen (Carlsbad, CA).
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4.2.2 Image Processing and PA Signal Decomposition (Unmixing)
The primary optical absorbers at visible wavelengths in this study were the myocardium
and DiI, which were separated by spectral decomposition. The PA signal is calculated using
the following equation:
PA = T ∗ ϕ ∗ µ. (4.1)
where PA is the photoacoustic signal in MPa, T is the dimensionless Grüneisen constant
that converts optical energy into acoustic pressure, ϕ is the laser fluence J/cm2, and µ is
the total absorption coefficient in cm-1 [139]. Total tissue absorption equals the sum of the
signals obtained, which is described by the following equation:
µtotal = Σ
M
m=1cm ∗ µm. (4.2)
where cm is the concentration of the mth absorber, µm is the absorption coefficient of the
mth absorber and M is the number of tissue absorbers. The fraction of sample absorbers is
written in matrix notation as:
Ac̄ = b̄. (4.3)
with A an MxN matrix containing the absorption coefficient of M absorbers at N wave-
lengths. c̄ is a 1xM vector containing a fractional distribution of M agents. b̄ is a 1xN vector
of a normalized PA signal over each wavelength [132]. The least squares of the residuals is
used to solve for ĉ:
ĉ = (AT ∗ A)−1 ∗ AT ∗ b̄. (4.4)
ĉ is a signal estimation of a specific absorber based on least squares This technique
separates DiI from the myocardium and other possible absorbers like hemoglobin.
4.2.3 Photoacoustic Imaging Experiments
Porcine Cardiac Tissue: All tissue obtained in this study was approved through the
University of Arizona Institutional Animal Care and Use Committee. Adult porcine hearts
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(n=5) were acquired from the University of Arizona Food Products and Safety Laboratory
and maintained at 4oC for up to 24 hours until imaging.
Validation and Calibration in Excised Myocardium: A porcine left ventricle was cut into
seven rectangular sections (approximately 1 x 1 x 0.5 cm). Samples were soaked in DiI
for 24 hours at different concentrations (0, 2.4, 4.8, 9.6, 38.4, 76.8, and 120 µg/ml) and
embedded in agarose gel. Volumetric photoacoustic and ultrasound images were collected
by scanning the linear array along the elevational axis with 100 µm increments. The average
PA signal was calculated over the region of interest (ROI), which was determined from the
co-registered B mode ultrasound image and excluded the tissue boundary. A calibration
curve was generated by plotting the average PA signal vs. the DiI concentration.
In Situ Porcine Heart Imaging: Three porcine hearts were cut proximal and distal to
the coronary artery, and a cannula was inserted into the Left Anterior Descending Coronary
Artery (LADCA), which was initially flushed with water using a syringe pump (KD Scientific
KDS230 KDS 230 Multi-Syringe Pump). Standard ultrasound helped identify the vessel
location, size, and structure. Cross sectional PA images were taken from 430 nm to 670 nm
(10 nm increments). The porcine LADCA was perfused with 2.4 µg/ml and maintained for
20 minutes, followed by imaging, flushing with water, and re-imaging with pulse echo (PE)
and PA. The process was repeated at incrementally higher concentrations (i.e., 12 µg/ml
and 60 µg/ml). The relative contribution of DiI at each pixel was determined from spectral
decomposition. The distribution of DiI was also used to calculate coronary artery diffusion
area and distance. Diffusion area was calculated by subtracting the background from the
DiI signal and setting a threshold value. The total number of pixels with DiI were multiplied
by the pixel size (0.05 mm X 0.05 mm) to determine the diffusion area. The center of
the LADCA was determined from the PE ultrasound image, and the diffusion distance was
calculated by extending a line from the LADCA center point radially outward. Continuous
pixel values along the line greater than background was used to calculate diffusion distance.
Imaging of DiI-coated Stent: A Cobalt chromium stent with a sinusoidal pattern was
designed in Solidworks R© and fabricated by Proto Labs R©. Half of the stent was dipped
into DiI/PCL (60 µg/ml DiI and PCL) solution and dried for 20 minutes; this process was
repeated three times. A coating of polydimethylsiloxane (PDMS) was also added to prevent
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short-term elution. The uncoated region served as a control to compare to the coated region.
The stent was initially imaged in water and, later, inserted into the brachiocephalic trunk
for both PA and PE imaging.
4.3 Results
4.3.1 Validation and Calibration in Excised Myocardium
Images of four of the seven myocardial samples are displayed in Figure 16. Wavelengths
of 550 nm and 660 nm represented the local maximum and minimum for DiI absorption in
the visible range. Whereas at 550 nm the PA image was dominated by DiI absorption, at
660 nm the image was dominated by the intrinsic absorption of the myocardium. In general,
the PA signal intensity increased linearly with concentration. The final column represents
the DiI concentration after unmixing the PA signal at all the wavelengths.
These data were used to generate a calibration curve for DiI in the excised myocardium.
The average PA signal (over the ROI) was plotted against the prepared DiI concentration
(Figure 17). The axes are displayed in octaves to match the distribution of prepared DiI
concentrations.
Figure 17 indicates a strong linear relationship spanning almost 8 octaves between
the DiI sample concentration and the amplitude of the PA signal. In addition, minute
concentrations of DiI (<2.4 µg/ml) could be detected at high spatial resolution (<300 µm)
deep in tissue (>5 mm). These favorable attributes of PA imaging were extended to study
transport in the porcine coronary artery and myocardium.
Imaging of the Porcine Heart (In Situ): DiI at 2.4 µg/ml was perfused into the LADCA for
15 seconds (Figure 18). The PA signal at 550 nm near branching vessels increased linearly
during the perfusion, demonstrating real-time capabilities of PA imaging for tracking drug
transport and diffusion.
Estimates of DiI diffusion in the porcine heart is presented in Figure 19. The PA
spectrum was dominated by absorption of the myocardium except at regions with high DiI.
Areas of DiI diffusion for 2.4, 12, and 60 µg/ml were calculated at 1.30, 1.75, and 3.30 mm2,
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Figure 16: Ultrasound and photoacoustic imaging of porcine myocardial samples
stained with DiI. Each row represents a sample stained with a different concentration
of DiI (0 µg/ml, 38.4 µg/ml, 76.8 µg/ml, and 120 µg/ml). Column A) Cross sectional
PE ultrasound images of samples embedded in AgaroseTM. Samples are outlined in green.
Column B) Corresponding PA signal at 550 nm (near peak of DiI absorption). Column C)
PA signal at 660 nm (low DiI absorption). Column D) Relative concentration of DiI after
spectral decomposition. Green scale bar represents 2 mm.
respectively. Therefore, an increase in DiI concentration led to an increased in diffusion area.
These results demonstrated that PA imaging can track transport of DiI, a drug surrogate.
In addition to diffusion area, we also calculated the diffusion distance from the center
of LADCA, which depended on the concentration (Figure 20). DiI diffused an average of
0.95 ± 0.37 mm, ranging from 0.6 mm to 1.5 mm (Figure 20C). These results suggest that
PA imaging can track transport several millimeters from the coronary into the myocardium.
Ultrasound and Photoacoustic Imaging of a DiI-coated stent: A cardiovascular stent
was fabricated to test if PA imaging could detect DiI coated on a stent placed inside a
blood vessel. Images of the DiI-coated cardiovascular stent are presented in Figure 21.
PA imaging was able to differentiate the coated vs. uncoated region in water and in the
brachiocephalic trunk (Figure 21D and 21F, respectively). These results demonstrated
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Figure 17: PA Calibration Curve for DiI. The pixel values over the ROI were averaged
and plotted against the prepared concentration of DiI for each sample. The equation for
the best fit line (dashed red) and R2 value are also indicated. All concentration values are
in µg/ml. Based on the PA signal without DiI (blue dashed line), the sensitivity of PA for
detecting the dye in the samples was approximately 2 µg/ml.
that PA imaging was able to detect DiI on a stent placed inside a large blood vessel.
4.4 Discussion
Our results demonstrated that PAIS is a nondestructive method that tracks drug delivery
in the porcine vasculature while providing excellent contrast, depth, and resolution. PAIS
was able to quantify the distribution of a drug surrogate at concentrations from 2.4 µg/ml
to 120 µg/ml. Perfusion of DiI into the coronary artery increased the PA signal in the
surrounding tissue greater than 1.5 millimeter away from the targeted vessel. PAIS was
also able to differentiate the brachiocephalic trunk from the coated and uncoated regions of
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Figure 18: Increase in PA Signal near LADCA during DiI Perfusion. (A) Cross
sectional PE image of an ex vivo porcine heart. (B) Co-registered PA image at 550 nm
during infusion of 2.4 µg/ml DiI. Vessel pressure was maintained at 70 mm Hg. C) Average
PA signal over time inside dashed green box during infusion of DiI. The PA signal increase
is observed in myocardial tissue adjacent to the coronary (CA) vessel. The scale bar denotes
2 mm.
a stent. Our results suggest that PAIS may be a valuable tool for tracking drug delivery
to a specific vessel and provide feedback on drugs loaded onto a vascular implant or DES.
In this regard, PAIS may help improve the design of a vascular implants, increase drug
retention and delivery to the coronaries arteries from DES, and reduce in-stent restenosis.
Our approach has not only demonstrated that PAIS may be a useful tool for assessing
drug delivery in vitro but could also be used in preclinical animal models of vascular disease.
For example, a porcine thoracic window to the coronary artery could provide time course
information about in vivo drug delivery [140]. Specifically, DES polymer degradation and
therapeutic drug transport could be monitored over time in the same animal thus minimizing
the number of animals used in preclinical studies. For TEVGs, PAIS could easily track in
vivo degradation and cellular infiltration using a sheep carotid model due to proximity of
the vessel to the skin or the rat abdominal aorta model. Our results further suggest that the
PA signal from the vascular graft and surrounding tissues could be used to estimate drug
concentrations thus providing real time feedback for improving vascular design.
To visualize drug delivery, this study implemented a drug surrogate with a peak absorp-
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Figure 19: Estimation of DiI diffusion in the heart near the LADCA. (A) Cross
sectional PE ultrasound image over LADCA. (B) Co-registered PA image at 550 nm with
a dynamic range of 40 dB. The PA spectra over regions of interest marked with “X” are
displayed in (C). Brown and blue regions are similar to the known absorption spectra of the
myocardium and DiI, respectively. (D) Co-registered PE (gray) and unmixed PA signal for
60 µg/ml DiI concentration (following flush). Green box identifies the ROI for cumulative
diffusion analysis. E) PA images over ROI (green box) for DiI concentration of 0 µg/ml
(100% water), 2.4 µg/ml, 12 µg/ml, and 60 µg/ml. f) Diffusion area for each concentration
based on PA signal over background. Scale bar is 2 mm.
tion near 550 nm. At this wavelength, penetration depth in cardiac tissue is about ∼5 mm
due to overlap in intrinsic background absorption (e.g., hemoglobin). However, if the drug
surrogate is exchanged for a near infrared (NIR) absorber, PAIS should be able to track drug
delivery even deeper (>10 mm) into tissue with less interference from background absorption
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Figure 20: Diffusion distance from LADCA. (A) Cross sectional ultrasound image of
the LADCA in the porcine heart. (B) Overlay of PE ultrasound (gray) and PA (hot) images
Scale bar = 2 mm. (C) Calculation of diffusion distance from LADCA based on signal above
threshold noise inside dashed box in (B). Diffusion distance for this example ranged from
0.6 to 1.5 mm. Scale bar = 1 mm.
[140]. In this case, it may be possible to use fewer wavelengths for spectral decomposition,
thereby simplifying the imaging procedure and scan time. Looking more into TEVGs, cur-
rently there is no fluorescently labeled TGFβ-2 available, but in vivo degradation could be
tracked by the incorporation of a dye into the fiber. For DES, most restenosis drugs absorb
in the ultraviolet range which limits penetration depth [141, 142]. Therefore, it could be
desirable to conjugate a small-molecule dye onto the drug to track delivery using PAIS. For
example, the 42’ hydroxyl group on rapamycin has shown great promise for conjugation of an
optically-absorbing dye. One group has successfully attached 7-bromo-4-nitrobenzofurazan,
a visible spectrum dye, onto rapamycin [143]. Conjugating rapamycin with a visible or NIR
absorber would facilitate PAIS for quantifying drug delivery to the coronary artery.
In order to track drug delivery, there are many confounding factors that affect the PA
signal in the heart: dye concentration, laser fluence, sample geometry, dye distribution,
background absorption, and photobleaching. To reduce effects of pulse-to-pulse variations of
the laser, we averaged the signal at each location over several pulses. Photobleaching of the
dye was also kept to a minimum by only exposing the samples to light while recording data
(typically less than 10 pulses at each location). To reduce effects of the geometry on the PA
signal during the calibration experiment, each sample was cut to a similar size and shape
and placed in the agarose gel at the same depth. The ROIs were chosen inside the sample
to reduce boundary effects of the PA signal. Finally, dye variations inside each sample were
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Figure 21: Pulse Echo and Photoacoustic Imaging of DiI-Coated Cardiovascular
Stent. (A) Zoomed-in photograph of sinusoidal pattern of stent; (B) Top view PE ul-
trasound image of stent at 7.1 MHz. (C) Top view photograph of stent with DiI/PCL +
PDMS coating on top half. (D)-(E) Co-registered PE ultrasound (gray) and PA (hot) at
550nm image (D = long view, E = cross view) of stent in water with coating on top half. (F)
Co-registered ultrasound and unmixed PA signal of stent implanted in the brachiocephalic
trunk. Scale bar 2 mm. Green box highlights the stent in the blood vessel.
reduced by soaking the samples for 24 hours in the dye. A similar protocol was employed
by Keyes et al. prior to PA imaging in porcine LADCA samples [119]. In that study, it was
assumed that 24 hours was sufficient for saturation of the dye in the tissue.
There were two other primary limitations in this study. First, the spatial resolution of
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∼300 µm was limited by the 5 MHz bandwidth of the ultrasound transducer. A higher fre-
quency ultrasound probe (e.g., >50 MHz) could be incorporated into our system to improve
the resolution to less than 50µm, which would be sufficient to track diffusion through layers
of the coronary wall [144]. Another limitation was the inability to directly apply our setup to
image the heart in vivo. Although transthoracic PA imaging is possible, penetration would
be limited to about 2 cm. In this case, intravascular ultrasound/PA (PA-IVUS) would be
the most practical solution for in vivo cardiac imaging of a DES. Currently, PA-IVUS has
been used to track the position of a stent and detect vulnerable plaque in animal models
[145, 146, 147, 148]. Such probes are being developed and tested by other groups with the
ultimate goal of clinical translation [146, 149, 150, 151, 152].
4.5 Conclusion
This study demonstrated that PA imaging offers excellent spatial resolution, penetration,
and contrast for tracking transport of a drug surrogate in the porcine vasculature. PAIS also
improves the specificity for estimating drug concentrations by separating the signal from
intrinsic background absorbers in the cardiac tissue. In the future, in vivo PA imaging of
drug retention and delivery may not only be possible in the coronaries but throughout the
native vasculature. This technique could improve TEVG and stent design by tracking drug
delivery and degradation noninvasively throughout multiple time points while minimizing




Throughout this work, we have investigated multiple vascular grafts to gain a better
understanding of how compliance and TGFβ2 affect vascular graft design, while demon-
strating a new method to evaluate graft drug delivery and degradation. In the TEVGs, we
were able to measure the graft’s in vivo vessel diameter, compliance, and maximum velocity
using doppler ultrasound. Immunohistochemistry results from the TEVGs were quantified
to determine the cell type (marcophage, SMC, and endothelial). Extracellular components,
collagen and elastin, were also measured to calculate deposition. In a stent, photoacoustic
imaging was used to determine drug surrogate diffusion into a porcine coronary over time.
In aim 1, compliance-matched and hypocompliant TEVGs were implanted into Sprague
Dawley rats for 28 day and imaged to evaluate the effect of compliance on the TEVG.
Next in aim 2, these implants were loaded with varying amounts of TGFβ2 (0, 10, and 100
ng/mg) and implanted in rats for an acute 5 day study to promote faster/increased cellular
infiltration. Lastly, in aim 3 we evaluated an alternative method to track in vivo construct
degradation, cellular infiltration, and drug release using photoacoustic imaging.
5.2 Summary of Results
5.2.1 Chapter 2: In-vivo assessment of a tissue engineered vascular graft com-
putationally optimized for target vessel compliance
In chapter two, TEVG compliance was manipulated by computationally tuning its lay-
ered composition or by manipulating a crosslinking agent (genipin). In particular, these
three acelluluar TEVGs were compared: a compliance-matched graft (CMgel - high gelatin
content), a hypocompliant PCL graft (HYPOpcl - high polycaprolactone content), and a
hypocompliant genipin graft (HYPOgen - equivalent composition as CMgel but hypocompli-
ant via increased genipin crosslinking). All constructs were implanted interpositionally into
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the abdominal aorta of 21 sprague Dawley rats (n=7, males=11, females=10) for 28 days,
imaged in vivo using ultrasound, explanted, and assessed for remodeling using immunofluo-
rescence and two photon excitation fluorescence imaging.
Compliance-matched grafts maintained their compliance compared to the hypocompli-
ant grafts through 4 weeks (p<0.05). Construct degradation and cellular infiltration was
increased in the CMgel and HYPOgen TEVGs. Contractile smooth muscle cell markers in
the proximal anastomosis of the graft were increased in the CMgel group compared to the
HYPOpcl (p=0.007) and HYPOgen grafts (p=0.04). Both hypocompliant grafts also had an
increased pro-inflammatory response (increased ratio of CD163 to CD86 in the mid-axial
location) compared to the CMgel group. Our results suggest that compliance matching using
a computational optimization approach leads to an improved acute (28 day) remodeling of
TEVGs.
5.2.2 Chapter 3: Modulating TGFβ2 Elution Alters the Acute Remodeling of
a Compliance-Matched Tissue Engineered Vascular Graft
In chapter 3, TGFβ2 is incorporated into the CMgel and HYPOpcl TEVGs to promote
cellular infiltration. TGFβ2 is a cytokine that plays a vital role in vascular remodeling and
cell cycle regulation, SMCs. In this work, electrospun compliance-matched and hypocompli-
ant TGFβ2 eluting TEVGs were implanted into Sprague Dawley rats for 5 days to observe
SMC infiltration and ECM production. TEVGs were fabricated using a combined compu-
tational and experimental approach to be either compliance-matched or twice as stiff as rat
aorta (hypocompliant). TGFβ2 concentrations of 0, 10, 100 ng/mg were added to both graft
types (n=3 in each group) and imaged in vivo using ultrasound. Histological markers (SMC,
macrophage, collagen, and elastin) were evaluated following explantation at 5 days.
In vivo ultrasound showed that the compliance-matched TEVGs became stiffer as TGFβ2
increased (100 ng/mg TEVGS compared to rat aorta, p<0.01) while all hypocompliant grafts
remained stiffer than control rat aorta. In vivo velocity and diameter were also not signifi-
cantly different than control vessels. For histology, the compliance-matched 10 ng/mg group
had an elevated SMC signal (myosin heavy chain) compared to the 0 and 100 ng/mg grafts
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(p=0.0009 & 0.0006 ). Compliance-matched TEVGs containing 100 ng/mg TGFβ2 had an
increase in collagen production (p<0.01), an increase in general immune response (p<0.05),
and a decrease in SMC infiltration to the 0 and 10 ng/mg groups. All hypocompliant groups
were found to be similar, suggesting a lower rate of TGFβ2 release in these TEVGs. Our
results suggest that TGFβ2 can modulates in vivo SMC phenotype over an acute time point,
which is consistent with our prior in vitro work.
5.2.3 Chapter 4: Tracking delivery of a drug surrogate in the porcine coronary
artery using photoacoustic imaging and spectroscopy
In chapter 4, we demonstrate real-time photoacoustic imaging and spectroscopy (PAIS)
using a wavelength-tunable visible laser and clinical ultrasound scanner to track cardiac drug
delivery. The photoacoustic signal was initially calibrated using porcine myocardial samples
soaked with a known concentration of a drug surrogate (DiI). Next, an in situ coronary artery
was perfused with DiI for 20 minutes and imaged to monitor dye transport in the tissue.
Finally, a partially DiI-coated stent was inserted into the porcine brachiocephalic trunk for
imaging. The photoacoustic signal was proportional to the DiI concentration between 2.4
and 120 µg/ml, and the dye was detected over 1.5 mm from the targeted coronary vessel.
Photoacoustic imaging was also able to differentiate the DiI-coated portion of the stent from
the uncoated region. These results suggest that PAIS can track drug delivery to cardiac
tissue and detect drugs loaded onto a stent with sub-mm precision. Future work using PAIS
may help improve TEVG and DES design and reduce the probability of restenosis.
5.3 Future Work and Limitations
This dissertation’s work is an initial step towards evaluating drug delivery and compli-
ance’s affect on vascular graft design. This work has helped establish a framework for future
studies in vivo and ex vivo work in the soft tissue biomechanics laboratory. This section of
the dissertation will be devoted towards the future direction of this work and the limitations.
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A primary component of this dissertation is the compliance of the vascular graft. As
stated throughout this work, a hypocompliant TEVG may disrupt the hemodynmaical envi-
ronment leading to intimal hyperplasia and ultimately causing loss of patency in the vessel.
The work in aim 1 was an initial attempt to isolate the effects of compliance by compar-
ing two hypocompliant controls (composition and crosslinking concentration) to a rat aorta
compliance-matched TEVG. The effects of compliance in this study could only be set apart
when both hypocompliant grafts were similar and the compliance-matched graft was differ-
ent. This study took a basic approach to evaluating compliance through composition and
crosslinking agent, while there are many other methods that could be used. For example,
another method to vary compliance could be through the modification of the construct’s
thickness, increased crosslinking duration, or the choice of TEVG material. These aforemen-
tioned methods could be used in conjunction with this work to further isolate the effects of
compliance. This dissertation helped to demonstrate the underlying hypothesis, but longer
time points may demonstrate such outcomes as a lower patency and increased intimal hy-
perplasia in the hypocompliant grafts and increased neovessel formation in the compliant
matched grafts.
In aim 2, the elution of TGFβ2 from the CMgel and HYPOpcl was evaluated in vivo
using a rat animal model for 5 days. While the results from this study were encouraging
with results matching prior in vitro work, the limited time points and sample size may
have limited the overall impact of the work. Specifically, the sample size of n=3 should be
expanded to n=7 to increase the power between each group. The duration of the study
should also be increased to include time points at one and three months. The longer time
points will allow help clarify the potential benefit of the growth factor. For example, at
one and three months there will be increased ECM deposition and cellular infiltration. We
would expect there to be an increase in collagen and neovessel formation in the low TGFβ2
concentration group. On the other hand, prolonged or exaggerated TGFβ2 release could
be detrimental to the construct as demonstrated in vascular injuries and cancer. Finding a
balance between TGFβ2 release and TEVG remodeling will be vital to the success of the
implant.
Another future direction with this TGFβ2 work would be to modify the release and
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concentration. TGFβ2 could be incorporated into a microparticle and the release could
be modified as shown in the work by Jhunjhunwala et al. using TGFβ1 [102]. The current
working hypothesis for TGFβ2 release would be to have a low release early to promote cellular
infiltration and a high short release later on to promote collagen development. Another
simple method to increase TGFβ2 release would be to modify the crosslinking method.
Currently, each construct is soak in genipin for 24 hours which, could cause any unbound
or loose TGFβ2 to be eluted into the solution. This problem could be fixed by modifying
the cross linking method to switch to ultraviolet light, vapor, chemical, or plasma treatment
[108].
For both aims 1 and 2, the rat was the primary focus for evaluating the remodeling of
a TEVG, but there are some limitations. While the rat offers a high throughput model to
test new ideas and larger groups, it lacks the hemodynamic, clotting, length implantation,
and immune reaction seen in humans. Moving towards a larger animal can help to overcome
some of these challenges and move the TEVG closer towards a clinic trial. For TEVGs
especially, the sheep carotid model is one of the best choices due to hemodynamics, clotting,
and the extended length (>5 cm) [30]. We have taken the next step and implanted our
HYPOpcl into a sheep carotid for 1 day. This study was cut short due to a surgical error that
damaged the vagus nerve of the sheep which disrupted the food digestion process and caused
the animal to be sacrificed. An image of the implanted construct is show in (Figure 22.
The graft was still patent at one day and this was confirmed by ultrasound. Initial histology
demonstrated no sign of platelet buildup or formation of a thrombus. In future, we hope
that this preliminary testing can be used as a stepping stone for future sheep testing.
In aim 3 of this dissertation work, we demonstrated that PA imaging has the potential
to track drug delivery and construct degradation. This method specifically evaluated the
diffusion of DiI into the porcine coronary tissue and myocardium. While the results of this
study are more of a proof of concept, this work demonstrates how important PA imaging
could be in future work and the translatability of this method. PA imaging offers the ability
to track cellular migration, construction degradation, and drug elution in a TEVG or vascular
implant. For example, this method could be incorporated by adding a unique fluorophore to
the construct, drug, or cells and tracking their intensity. The TEVG will start with an initial
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Figure 22: The HYPOpcl TEVG (blue) implanted into the sheep carotid. The graft was 9
cm in length and had a wall thickness of 400 µm.
absorbance and over time the user will PA image the construct and compare the results to
the original values. A decrease in the absorbance intensity could signal a release of drug,
the construct degraded, or cellular death depending on the tagged component. The ideal
fluorophore would be in the near infrared region to help reduce intrinsic absorber in the tissue.
The absorbance intensity from the fluorophore will demonstrate how much degradation or
drug delivery has occurred from a loss of signal. The ideal fluorophore would be in the near
infrared region to help reduce intrinsic absorber in the tissue.
PA imaging also has the ability to be used in other animals models besides the porcine.
The ideal animal model for imaging a TEVG/vascular implant would be a large vessel near
the surface. The rat animal model used in aims 1 and 2 would not visable with the current
PA imaging setup in aim 3 as the resolution of the system is too large, 300 µm. The
ultrasound probe would need to be increase from 7.1 Mhz to 60 Mhz in order to view the
TEVG which was on average a 100 µm. The 7.1 Mhz setup in aim 3 could be used for
imaging the sheep carotid discussed in the this section, but it would be recommended that
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the probe be increased to around 30 Mhz. It is recommended that future work should use a
higher Mhz probe to increase the resolution and make this method more viable.
5.4 Conclusions
Previous work has demonstrated that a stiff or hypocompliant TEVG negatively affect
vascular remodel and patency, but has been unable to tune compliance to a specific value. In
this work, we demonstrate that our computational/experimental approach can fine tune the
compliance of a vascular graft by composition and takes it a step further by modifying com-
pliance by crosslinking as well. We confirm that matching a TEVG to the native vasculature
will positively impact graft remodeling. Specifically, a compliance-matched construct pro-
motes an increase in SMC, positive macrophage remodeling, and increased collagen content
in the TEVG.
To promote earlier SMC infiltration into the TEVG and collagen deposition, we in-
fused the compliance-matched and hypocompliant constructs with varying concentration of
TGFβ2. This growth factor has previously shown that it can modulate SMC phenotype
depending on the concentration. Specifically, at low TGFβ2 concentration this factor will
promote cellular migration and proliferation, while at higher concentrations it arrests cel-
lular growth that promotes collagen development. This TGFβ2 response was confirmed in
our compliance-matched scaffolds. One surprising result from the inclusion of TGFβ2 in
the compliance-matched scaffolds was that as concentration increased the scaffold became
stiffer. While the compliance-matched scaffolds demonstrated the majority of significant
results, all TGFβ2 concentrations in the hypocompliant constructs had no differences be-
tween any groups in the study. This lack of differences seen in the hypocompliant constructs
demonstrated the importance of scaffold degradation in the release of TGFβ2. For exam-
ple, the compliance-matched construct in aim one had over 70% degradation by 4 weeks
compared to about 30% seen in the hypocompliant grafts. Digging deeper into previous
work by Ardila et al., she showed that the compliance-matched scaffold should have over a
40x higher release than the hypocompliant construct. This lack of release of TGFβ2 in the
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hypocompliant scaffolds accounts for the lack of differences in the results.
Moving forward, this dissertation has also developed a method to evaluate drug delivery
and track construct degradation noninvasively using photoacoustic imaging and spectroscopy.
By including a known absorbing agent into the scaffold or drug, the user would be able to
identify drug release or scaffold degradation. This method would be most feasible in a larger
animal due to limited spatial resolution of the ultrasound technology. We hope that this work


























































































































Figure S1: Hypocompliant cross sectional immunohistochemistry quantification of αSMA,























































































































Figure S2: Hypocompliant longitudinal immunohistochemistry quantification of αSMA,








Figure S3: Hypocompliant cross sectional immunohistochemistry quantification of αSMA,
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folds for vascular tissue engineering,” J Control Release, vol. 299, pp. 44–52, 04 2019.
[28] E. A. Tamimi, D. C. Ardila, B. D. Ensley, R. S. Kellar, and J. Vande Geest, “Com-
putationally optimizing the compliance of multilayered biomimetic tissue engineered
vascular grafts,” Journal of Biomechanical Engineering, vol. 141(2019), Feb 2019.
[29] D. C. Ardila, E. Tamimi, F. L. Danford, D. G. Haskett, R. S. Kellar, T. Doetschman,
and J. P. Vande Geest, “TGFβ2 differentially modulates smooth muscle cell prolifera-
tion and migration in electrospun gelatin-fibrinogen constructs,” Biomaterials, vol. 37,
pp. 164–173, Jan 2015.
84
[30] D. D. Swartz and S. T. Andreadis, “Animal models for vascular tissue-engineering,”
Curr Opin Biotechnol, vol. 24, no. 5, pp. 916–25, 2013.
[31] M. J. Byrom, P. G. Bannon, G. H. White, and M. K. Ng, “Animal models for the
assessment of novel vascular conduits,” J Vasc Surg, vol. 52, pp. 176–195, Jul 2010.
[32] K. J. Furdella, S. Higuchi, A. Behrangzade, K. Kim, W. R. Wagner, and J. P.
Vande Geest, “In-vivo assessment of a tissue engineered vascular graft computation-
ally optimized for target vessel compliance,” Acta Biomater, vol. 123, pp. 298–311, 03
2021.
[33] W. M. Abbott, J. Megerman, J. E. Hasson, G. Litalien, and D. F. Warnock, “Effect of
compliance mismatch on vascular graft patency,” Journal of Vascular Surgery, vol. 5,
no. 2, pp. 376–382, 1987.
[34] S. F. Stewart and D. J. Lyman, “Effects of an artery/vascular graft compliance mis-
match on protein transport: a numerical study,” Ann Biomed Eng, vol. 32, pp. 991–
1006, Jul 2004.
[35] W. Trubel, H. Schima, A. Moritz, F. Raderer, A. Windisch, R. Ullrich, U. Windberger,
U. Losert, and P. Polterauer, “Compliance mismatch and formation of distal anasto-
motic intimal hyperplasia in externally stiffened and lumen-adapted venous grafts,”
Eur J Vasc Endovasc Surg, vol. 10, pp. 415–423, Nov 1995.
[36] M. Zhu, Y. Wu, W. Li, X. Dong, H. Chang, K. Wang, P. Wu, J. Zhang, G. Fan,
L. Wang, J. Liu, H. Wang, and D. Kong, “Biodegradable and elastomeric vascular
grafts enable vascular remodeling,” Biomaterials, vol. 183, pp. 306–318, 11 2018.
[37] V. A. Kumar, J. M. Caves, C. A. Haller, E. Dai, L. Liu, S. Grainger, and E. L.
Chaikof, “Acellular vascular grafts generated from collagen and elastin analogs,” Acta
Biomater, vol. 9, pp. 8067–8074, Sep 2013.
[38] N. L’Heureux, N. Dusserre, G. Konig, B. Victor, P. Keire, T. N. Wight, N. A. Chronos,
A. E. Kyles, C. R. Gregory, G. Hoyt, R. C. Robbins, and T. N. McAllister, “Human
tissue-engineered blood vessels for adult arterial revascularization,” Nat. Med., vol. 12,
pp. 361–365, Mar 2006.
[39] P. Gupta, K. L. Lorentz, D. G. Haskett, E. M. Cunnane, A. K. Ramaswamy, J. S.
Weinbaum, D. A. Vorp, and B. B. Mandal, “Bioresorbable silk grafts for small diame-
85
ter vascular tissue engineering applications: In vitro and in vivo functional analysis,”
Acta Biomater, vol. 105, pp. 146–158, Mar 2020.
[40] K. W. Lee, P. S. Gade, L. Dong, Z. Zhang, A. M. Aral, J. Gao, X. Ding, C. E. T.
Stowell, M. U. Nisar, K. Kim, D. P. Reinhardt, M. G. Solari, V. S. Gorantla, A. M.
Robertson, and Y. Wang, “A biodegradable synthetic graft for small arteries matches
the performance of autologous vein in rat carotid arteries,” Biomaterials, vol. 181,
pp. 67–80, 10 2018.
[41] R. M. Nezarati, M. B. Eifert, D. K. Dempsey, and E. Cosgriff-Hernandez, “Electrospun
vascular grafts with improved compliance matching to native vessels,” J. Biomed.
Mater. Res. Part B Appl. Biomater., vol. 103, pp. 313–323, Feb 2015.
[42] X. Wang, P. Lin, Q. Yao, and C. Chen, “Development of small-diameter vascular
grafts,” World J Surg, vol. 31, pp. 682–689, Apr 2007.
[43] J. G. Nemeno-Guanzon, S. Lee, J. R. Berg, Y. H. Jo, J. E. Yeo, B. M. Nam, Y. G. Koh,
and J. I. Lee, “Trends in tissue engineering for blood vessels,” J. Biomed. Biotechnol.,
vol. 2012, p. 956345, 2012.
[44] R. Y. Kannan, H. J. Salacinski, P. E. Butler, G. Hamilton, and A. M. Seifalian,
“Current status of prosthetic bypass grafts: a review,” J. Biomed. Mater. Res. Part
B Appl. Biomater., vol. 74, pp. 570–581, Jul 2005.
[45] E. Tamimi, D. C. Ardila, D. G. Haskett, T. Doetschman, M. J. Slepian, R. S. Kellar,
and J. P. Vande Geest, “Biomechanical Comparison of Glutaraldehyde-Crosslinked
Gelatin Fibrinogen Electrospun Scaffolds to Porcine Coronary Arteries,” J Biomech
Eng, vol. 138(1)(2016), p. 061003, Jan 2016.
[46] D. Haskett, E. Speicher, M. Fouts, D. Larson, M. Azhar, U. Utzinger, and
J. Vande Geest, “The effects of angiotensin II on the coupled microstructural and
biomechanical response of C57BL/6 mouse aorta,” J Biomech, vol. 45, pp. 772–779,
Mar 2012.
[47] D. Haskett, M. Azhar, U. Utzinger, and J. P. V. Geest, “Progressive alterations in
microstructural organization and biomechanical response in the apoe mouse model of
aneurysm,” Biomatter, vol. 3, no. 3, p. e24648, 2013.
[48] D. Haskett, J. J. Doyle, C. Gard, H. Chen, C. Ball, M. A. Estabrook, A. C. Encinas,
H. C. Dietz, U. Utzinger, J. P. Vande Geest, and M. Azhar, “Altered tissue behavior of
86
a non-aneurysmal descending thoracic aorta in the mouse model of Marfan syndrome,”
Cell Tissue Res., vol. 347, pp. 267–277, Jan 2012.
[49] J. T. Keyes, D. G. Haskett, U. Utzinger, M. Azhar, and J. P. Vande Geest, “Adap-
tation of a planar microbiaxial optomechanical device for the tubular biaxial mi-
crostructural and macroscopic characterization of small vascular tissues,” Journal of
Biomechanical Engineering, vol. 133, no. 7, pp. 075001–075001, 2011.
[50] J. T. Keyes, D. R. Lockwood, U. Utzinger, L. G. Montilla, R. S. Witte, and J. P.
Vande Geest, “Comparisons of planar and tubular biaxial tensile testing protocols of
the same porcine coronary arteries,” Annals of Biomedical Engineering, vol. 41, no. 7,
pp. 1579–1591, 2013.
[51] J. T. Keyes, S. M. Borowicz, J. H. Rader, U. Utzinger, M. Azhar, and J. P.
Vande Geest, “Design and demonstration of a microbiaxial optomechanical device
for multiscale characterization of soft biological tissues with two-photon microscopy,”
Microsc. Microanal., vol. 17, pp. 167–175, Apr 2011.
[52] S. Harrison, E. Tamimi, J. Uhlorn, T. Leach, and J. P. Vande Geest, “Computationally
optimizing the compliance of a biopolymer based tissue engineered vascular graft,”
Journal of Biomechanical Engineering, vol. 138, no. 1, p. 0145051-0145055, 2016.
[53] N. R. Tai, H. J. Salacinski, A. Edwards, G. Hamilton, and A. M. Seifalian, “Com-
pliance properties of conduits used in vascular reconstruction,” Br J Surg, vol. 87,
pp. 1516–1524, Nov 2000.
[54] J. Guan, M. S. Sacks, E. J. Beckman, and W. R. Wagner, “Biodegradable poly(ether
ester urethane)urea elastomers based on poly(ether ester) triblock copolymers and
putrescine: synthesis, characterization and cytocompatibility,” Biomaterials, vol. 25,
pp. 85–96, Jan 2004.
[55] M. Y. Park, S. E. Jung, J. Y. Byun, J. H. Kim, and G. E. Joo, “Effect of beam-flow
angle on velocity measurements in modern doppler ultrasound systems,” American
Journal of Roentgenology, vol. 198, no. 5, pp. 1139–1143, 2012.
[56] S. R. Peyton, P. D. Kim, C. M. Ghajar, D. Seliktar, and A. J. Putnam, “The effects
of matrix stiffness and RhoA on the phenotypic plasticity of smooth muscle cells in a
3-D biosynthetic hydrogel system,” Biomaterials, vol. 29, pp. 2597–2607, Jun 2008.
87
[57] B. Yi, Y. Shen, H. Tang, X. Wang, B. Li, and Y. Zhang, “Stiffness of Aligned Fibers
Regulates the Phenotypic Expression of Vascular Smooth Muscle Cells,” ACS Appl
Mater Interfaces, vol. 11, pp. 6867–6880, Feb 2019.
[58] P. F. Sanchez, E. M. Brey, and J. C. Briceno, “Endothelialization mechanisms in
vascular grafts,” J Tissue Eng Regen Med, vol. 12, pp. 2164–2178, 11 2018.
[59] S. K. Norouzi and A. Shamloo, “Bilayered heparinized vascular graft fabricated by
combining electrospinning and freeze drying methods,” Mater Sci Eng C Mater Biol
Appl, vol. 94, pp. 1067–1076, Jan 2019.
[60] K. T. Shalumon, S. Deepthi, M. S. Anupama, S. V. Nair, R. Jayakumar, and K. P.
Chennazhi, “Fabrication of poly (L-lactic acid)/gelatin composite tubular scaffolds
for vascular tissue engineering,” Int. J. Biol. Macromol., vol. 72, pp. 1048–1055, Jan
2015.
[61] M. Zhu, Z. Wang, J. Zhang, L. Wang, X. Yang, J. Chen, G. Fan, S. Ji, C. Xing,
K. Wang, Q. Zhao, Y. Zhu, D. Kong, and L. Wang, “Circumferentially aligned fibers
guided functional neoartery regeneration in vivo,” Biomaterials, vol. 61, pp. 85–94,
2015.
[62] Y. Pan, X. Zhou, Y. Wei, Q. Zhang, T. Wang, M. Zhu, W. Li, R. Huang, R. Liu,
J. Chen, G. Fan, K. Wang, D. Kong, and Q. Zhao, “Small-diameter hybrid vascular
grafts composed of polycaprolactone and polydioxanone fibers,” Sci Rep, vol. 7, no. 1,
p. 3615, 2017.
[63] J. Y. Wong, A. Velasco, P. Rajagopalan, and Q. Pham, “Directed movement of vas-
cular smooth muscle cells on gradient-compliant hydrogels,” Langmuir, vol. 19, no. 5,
pp. 1908–1913, 2003.
[64] H. G. Sundararaghavan, G. A. Monteiro, N. A. Lapin, Y. J. Chabal, J. R. Miksan, and
D. I. Shreiber, “Genipin-induced changes in collagen gels: correlation of mechanical
properties to fluorescence,” J Biomed Mater Res A, vol. 87, pp. 308–320, Nov 2008.
[65] G. Fessel, J. Cadby, S. Wunderli, R. van Weeren, and J. G. Snedeker, “Dose- and
time-dependent effects of genipin crosslinking on cell viability and tissue mechanics -
toward clinical application for tendon repair,” Acta Biomater, vol. 10, pp. 1897–1906,
May 2014.
88
[66] R. A. Allen, W. Wu, M. Yao, D. Dutta, X. Duan, T. N. Bachman, H. C. Cham-
pion, D. B. Stolz, A. M. Robertson, K. Kim, J. S. Isenberg, and Y. Wang, “Nerve
regeneration and elastin formation within poly(glycerol sebacate)-based synthetic ar-
terial grafts one-year post-implantation in a rat model,” Biomaterials, vol. 35, no. 1,
pp. 165–73, 2014.
[67] S. Timraz, R. Rezgui, S. M. Boularaoui, and J. C. M. Teo, “Stiffness of extracellular
matrix components modulates the phenotype of human smooth muscle cells in vitro
and allows for the control of properties of engineered tissues,” Procedia Engineering,
vol. 110, pp. 29–36, 2015.
[68] S. A. Xie, T. Zhang, J. Wang, F. Zhao, Y. P. Zhang, W. J. Yao, S. S. Hur, Y. T.
Yeh, W. Pang, L. S. Zheng, Y. B. Fan, W. Kong, X. Wang, J. J. Chiu, and J. Zhou,
“Matrix stiffness determines the phenotype of vascular smooth muscle cell in vitro
and in vivo: Role of dna methyltransferase 1,” Biomaterials, vol. 155, pp. 203–216,
2018.
[69] Y. Wang, J. Bao, X. Wu, Q. Wu, Y. Li, Y. Zhou, L. Li, and H. Bu, “Genipin crosslink-
ing reduced the immunogenicity of xenogeneic decellularized porcine whole-liver ma-
trices through regulation of immune cell proliferation and polarization,” Sci Rep,
vol. 6, p. 24779, Apr 2016.
[70] S. de Valence, J. C. Tille, D. Mugnai, W. Mrowczynski, R. Gurny, M. Moller, and
B. H. Walpoth, “Long term performance of polycaprolactone vascular grafts in a rat
abdominal aorta replacement model,” Biomaterials, vol. 33, no. 1, pp. 38–47, 2012.
[71] M. D. Rekhter, “Collagen synthesis in atherosclerosis: too much and not enough,”
Cardiovasc Res, vol. 41, pp. 376–384, Feb 1999.
[72] E. Adiguzel, P. J. Ahmad, C. Franco, and M. P. Bendeck, “Collagens in the progression
and complications of atherosclerosis,” Vasc Med, vol. 14, pp. 73–89, Feb 2009.
[73] T. Yeung, P. C. Georges, L. A. Flanagan, B. Marg, M. Ortiz, M. Funaki, N. Zahir,
W. Ming, V. Weaver, and P. A. Janmey, “Effects of substrate stiffness on cell mor-
phology, cytoskeletal structure, and adhesion,” Cell Motil Cytoskeleton, vol. 60, no. 1,
pp. 24–34, 2005.
[74] C. M. Lo, H. B. Wang, M. Dembo, Y. L. Wang, and Y. L. Wang, “Cell movement is
guided by the rigidity of the substrate,” Biophys. J., vol. 79, pp. 144–152, Jul 2000.
89
[75] Z. Wang, W. Zheng, Y. Wu, J. Wang, X. Zhang, K. Wang, Q. Zhao, D. Kong, T. Ke,
and C. Li, “Differences in the performance of pcl-based vascular grafts as abdominal
aorta substitutes in healthy and diabetic rats,” Biomater Sci, vol. 4, no. 10, pp. 1485–
92, 2016.
[76] B. Jiang, R. Suen, J. J. Wang, Z. J. Zhang, J. A. Wertheim, and G. A. Ameer,
“Mechanocompatible polymer-extracellular-matrix composites for vascular tissue en-
gineering,” Adv Healthc Mater, vol. 5, no. 13, pp. 1594–605, 2016.
[77] W. Wu, R. A. Allen, and Y. Wang, “Fast-degrading elastomer enables rapid remodel-
ing of a cell-free synthetic graft into a neoartery,” Nat Med, vol. 18, no. 7, pp. 1148–53,
2012.
[78] Y. Yang, D. Lei, H. Zou, S. Huang, Q. Yang, S. Li, F. L. Qing, X. Ye, Z. You, and
Q. Zhao, “Hybrid electrospun rapamycin-loaded small-diameter decellularized vascu-
lar grafts effectively inhibit intimal hyperplasia,” Acta Biomater, vol. 97, pp. 321–332,
2019.
[79] A. Mahara, T. Sakuma, N. Mihashi, T. Moritan, and T. Yamaoka, “Accelerated
endothelialization and suppressed thrombus formation of acellular vascular grafts
by modifying with neointima-inducing peptide: A time-dependent analysis of graft
patency in rat-abdominal transplantation model,” Colloids Surf B Biointerfaces,
vol. 181, pp. 806–813, 2019.
[80] A. Nieponice, L. Soletti, J. Guan, Y. Hong, B. Gharaibeh, T. M. Maul, J. Huard,
W. R. Wagner, and D. A. Vorp, “In vivo assessment of a tissue-engineered vascular
graft combining a biodegradable elastomeric scaffold and muscle-derived stem cells in
a rat model,” Tissue Eng Part A, vol. 16, no. 4, pp. 1215–23, 2010.
[81] L. Soletti, A. Nieponice, Y. Hong, S. H. Ye, J. J. Stankus, W. R. Wagner, and D. A.
Vorp, “In vivo performance of a phospholipid-coated bioerodable elastomeric graft for
small-diameter vascular applications,” J Biomed Mater Res A, vol. 96, no. 2, pp. 436–
48, 2011.
[82] E. Pektok, B. Nottelet, J. C. Tille, R. Gurny, A. Kalangos, M. Moeller, and B. H.
Walpoth, “Degradation and healing characteristics of small-diameter poly(epsilon-
caprolactone) vascular grafts in the rat systemic arterial circulation,” Circulation,
vol. 118, no. 24, pp. 2563–70, 2008.
[83] L. A. Ruiz-Taylor, T. L. Martin, F. G. Zaugg, K. Witte, P. Indermuhle, S. Nock, and
P. Wagner, “Monolayers of derivatized poly(L-lysine)-grafted poly(ethylene glycol)
90
on metal oxides as a class of biomolecular interfaces,” Proc. Natl. Acad. Sci. U.S.A.,
vol. 98, pp. 852–857, Jan 2001.
[84] L. L. Huang-Lee, D. T. Cheung, and M. E. Nimni, “Biochemical changes and cytotox-
icity associated with the degradation of polymeric glutaraldehyde derived crosslinks,”
J. Biomed. Mater. Res., vol. 24, pp. 1185–1201, Sep 1990.
[85] J. E. Gough, C. A. Scotchford, and S. Downes, “Cytotoxicity of glutaraldehyde
crosslinked collagen/poly(vinyl alcohol) films is by the mechanism of apoptosis,” J.
Biomed. Mater. Res., vol. 61, pp. 121–130, Jul 2002.
[86] A. Fernandez-Colino, F. Wolf, S. Rutten, T. Schmitz-Rode, J. C. Rodriguez-Cabello,
S. Jockenhoevel, and P. Mela, “Small caliber compliant vascular grafts based on
elastin-like recombinamers for in situ tissue engineering,” Front Bioeng Biotechnol,
vol. 7, p. 340, 2019.
[87] K. J. Furdella, R. S. Witte, and J. P. Vande Geest, “Tracking delivery of a drug sur-
rogate in the porcine heart using photoacoustic imaging and spectroscopy,” J Biomed
Opt, vol. 22, p. 41016, 04 2017.
[88] C. Boileau, D. C. Guo, N. Hanna, E. S. Regalado, D. Detaint, L. Gong, M. Varret,
and S. K. Prakash, “TGFB2 mutations cause familial thoracic aortic aneurysms and
dissections associated with mild systemic features of Marfan syndrome,” Nat Genet,
vol. 44, pp. 916–921, Jul 2012.
[89] N. W. Ramnath, L. J. Hawinkels, P. M. van Heijningen, L. te Riet, M. Paauwe,
M. Vermeij, A. H. Danser, R. Kanaar, P. ten Dijke, and J. Essers, “Fibulin-4 deficiency
increases TGF- signalling in aortic smooth muscle cells due to elevated TGF-2 levels,”
Sci Rep, vol. 5, p. 16872, Nov 2015.
[90] M. Azhar, K. Brown, C. Gard, H. Chen, S. Rajan, D. A. Elliott, M. V. Stevens,
T. D. Camenisch, S. J. Conway, and T. Doetschman, “Transforming growth factor
Beta2 is required for valve remodeling during heart development,” Dev Dyn, vol. 240,
pp. 2127–2141, Sep 2011.
[91] T. Doetschman, J. V. Barnett, R. B. Runyan, T. D. Camenisch, R. L. Heimark, H. L.
Granzier, S. J. Conway, and M. Azhar, “Transforming growth factor beta signaling
in adult cardiovascular diseases and repair,” Cell Tissue Res, vol. 347, pp. 203–223,
Jan 2012.
91
[92] A. C. Braverman, K. M. Harris, R. J. Kovacs, and B. J. Maron, “Eligibility and
Disqualification Recommendations for Competitive Athletes With Cardiovascular Ab-
normalities: Task Force 7: Aortic Diseases, Including Marfan Syndrome: A Scientific
Statement From the American Heart Association and American College of Cardiol-
ogy,” J Am Coll Cardiol, vol. 66, pp. 2398–2405, Dec 2015.
[93] I. Toma and T. A. McCaffrey, “Transforming growth factor- and atherosclerosis: inter-
woven atherogenic and atheroprotective aspects,” Cell Tissue Res, vol. 347, pp. 155–
175, Jan 2012.
[94] S. S. Rensen, P. A. Doevendans, and G. J. van Eys, “Regulation and characteristics
of vascular smooth muscle cell phenotypic diversity,” Neth Heart J, vol. 15, no. 3,
pp. 100–108, 2007.
[95] J. A. Beamish, P. He, K. Kottke-Marchant, and R. E. Marchant, “Molecular regu-
lation of contractile smooth muscle cell phenotype: implications for vascular tissue
engineering,” Tissue Eng Part B Rev, vol. 16, pp. 467–491, Oct 2010.
[96] S. Mii, J. A. Ware, and K. C. Kent, “Transforming growth factor-beta inhibits human
vascular smooth muscle cell growth and migration,” Surgery, vol. 114, pp. 464–470,
Aug 1993.
[97] L. Engel and U. Ryan, “TGF-beta 1 reverses PDGF-stimulated migration of human
aortic smooth muscle cells in vitro,” In Vitro Cell Dev Biol Anim, vol. 33, pp. 443–451,
Jun 1997.
[98] M. A. Moses, M. Klagsbrun, and Y. Shing, “The role of growth factors in vascular
cell development and differentiation,” Int Rev Cytol, vol. 161, pp. 1–48, 1995.
[99] E. L. Low, A. H. Baker, and A. C. Bradshaw, “TGF, smooth muscle cells and coronary
artery disease: a review,” Cell Signal, vol. 53, pp. 90–101, 01 2019.
[100] X. Guo and S. Y. Chen, “Transforming growth factor- and smooth muscle differenti-
ation,” World J Biol Chem, vol. 3, pp. 41–52, Mar 2012.
[101] K. Kubota, J. Okazaki, O. Louie, K. C. Kent, and B. Liu, “TGF-beta stimulates
collagen (I) in vascular smooth muscle cells via a short element in the proximal collagen
promoter,” J Surg Res, vol. 109, pp. 43–50, Jan 2003.
92
[102] S. Jhunjhunwala, S. C. Balmert, G. Raimondi, E. Dons, E. E. Nichols, A. W. Thom-
son, and S. R. Little, “Controlled release formulations of IL-2, TGF-1 and rapamycin
for the induction of regulatory T cells,” J Control Release, vol. 159, pp. 78–84, Apr
2012.
[103] K. Ley, “M1 Means Kill; M2 Means Heal,” J Immunol, vol. 199, pp. 2191–2193, 10
2017.
[104] F. O. Martinez and S. Gordon, “The M1 and M2 paradigm of macrophage activation:
time for reassessment,” F1000Prime Rep, vol. 6, p. 13, 2014.
[105] N. Hibino, D. Mejias, N. Pietris, E. Dean, T. Yi, C. Best, T. Shinoka, and C. Breuer,
“The innate immune system contributes to tissue-engineered vascular graft perfor-
mance,” FASEB J, vol. 29, pp. 2431–2438, Jun 2015.
[106] C. J. Ferrante and S. J. Leibovich, “Regulation of Macrophage Polarization and
Wound Healing,” Adv Wound Care (New Rochelle), vol. 1, pp. 10–16, Feb 2012.
[107] S. H. Wrzesinski, Y. Y. Wan, and R. A. Flavell, “Transforming growth factor-beta
and the immune response: implications for anticancer therapy,” Clin Cancer Res,
vol. 13, pp. 5262–5270, Sep 2007.
[108] C. E. Campiglio, N. Contessi Negrini, S. Farè, and L. Draghi, “Cross-Linking Strate-
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